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1 INTRODUCTION 
1.1 Tumorigenesis 
 
To stay healthy, a multicellular organism has to maintain homeostasis.  Different 
regulatory processes are required to keep the whole organism in a state of balance. It is 
essential that the cells forming the different tissues communicate and this involves 
several regulatory pathways, through which the cells send and receive signals that 
control cell division, differentiation or apoptotic cell death. A neoplastic cell is a cell 
that proliferates without control and colonizes territories normally reserved for other 
cells. The tumour that is formed in consequence of proliferation of neoplastic cells is a 
growing mass without any function for the organism as a whole. As long as the 
neoplastic cells remain clustered together in a single mass, the tumour is benign. If the 
neoplastic cells acquire the capacity to invade other tissues or form distant colonies 
(metastases), the tumour is malignant and defined as a cancer. 
The transition of a normal to a neoplastic cell is mainly due changes of the genetic 
program, which can have different origins:  
• DNA damage caused by environmental agents such as chemical 
carcinogens, radiation 
• deregulation by oncogenic viruses (including alteration of regulatory 
pathways by viral oncoproteins) 
• spontaneous mutations that occur mainly during replication or mitosis 
• inherited mutations that confer predisposition to neoplastic cell 
proliferation 
It is generally accepted that the formation of a neoplasm cannot be generated by a single 
mutation [1]. The number of genetic alterations needed to change a normal into a cancer 
cell varies according to the type of cancer and the type of alteration. Tumours can be 
classified as liquid or solid. Liquid tumours are composed of neoplastic cells whose 
precursors are normally mobile (i.e. leukaemia, lymphoma [1]). Solid tumours are 
composed of epithelial or mesenchymal cells that normally are immobile. It is generally 
assumed that liquid tumours require only 1 or 2 mutations to develop [2] whereas for 
solid tumours in adults at least 3 mutations are required [3].  
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Hanahan and Weinberg [4] have summarized the capabilities a cell must acquire to 
become a cancer cell:  
1) growth signal autonomy  
2) evasion of apoptosis 
3) insensitivity to antigrowth signals  
4) sustained angiogenesis 
5) limitless replicative potential and 
6) capacity to invade tissue and grow at metastatic sites 
The number of mutations required to gain these abilities varies. For example, in some 
cells mutation of the TP53 gene facilitates both cell proliferation and evasion of 
apoptosis whereas in other cancers, several mutations additional to tumour related genes 
may be required to attain these capabilities. While the number of mutations necessary to 
form a cancer cell is variable, the end stage, a cancer cell, is invariant and mutations in 
different sets of genes may lead to the same phenotype. As is to be expected from the 
functional changes that define the malignant phenotype, the proteins encoded by these 
cancer genes are often involved in pathways that regulate growth, apoptosis, 
angiogenesis and replication. For example, the p53 protein is a transcription factor that 
inhibits cell growth and stimulates cell death. The p53 pathway (Fig 1-1-b) can be 
disrupted by point mutation in the p53 gene, or by any other alteration on the genes 
involved in the pathway. The pathway itself rather than its single components is the 
functional target of the oncogenic alterations that promote cancer development. 
Nevertheless, it is important to identify the specific genes that are subject to oncogenic 
alterations as this knowledge can help to determine which pathways have been hit in a 
certain type of cancer. 
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Fig 1-1. Rb (a) and p53 (b) pathways. Diamonds indicate protein-protein interactions, 
arrows and T-bars indicate transcriptional induction and repression, respectively. Small 
circled “P”, “OH” and “Ub” represent covalently attached phosphate, hydroxyl and ubiquitin 
groups, respectively (adapted from Nature Reviews Genetics, November 2003, Volume 4). 
 
1.2 Cancer genes 
 
In general three types of genes can be distinguished that can be the target of oncogenic 
alterations: oncogenes, tumour suppressor and stability genes [1]. 
 
1.2.1 Oncogenes 
 
An oncogene may be defined as a derivate of a normal gene (proto-oncogene) that can 
induce a normal cell to become a cancer cell under certain circumstances. Most proto-
oncogenes encode proteins that participate in the regulation of growth and/or 
differentiation of normal cells. There are different ways by which a proto-oncogene can 
become an oncogene:  
• the gene may be altered by a small change in sequence such as point mutation 
which results in activation of the gene product irrespective of regulatory input 
(e.g. K-ras activated by point mutations in codons 12 and 61 in adenomas and 
adenocarcinomas of the colon [5]) 
• the gene may be altered by a chromosomal translocation that involves breakage 
and rejoining of the DNA . Such alterations can result in a hyperactive fusion 
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protein, or – if the translocation has brought into proximity a regulatory DNA 
sequence – that causes increased amounts of normal transcripts with concomitant 
overproduction of the encoded protein (for example in chronic myelogenous 
leukaemia with the Philadelphia chromosome) 
• errors in DNA replication can cause gene amplification. This can result in 
production of increased amounts of a protein that is structurally normal (erbB-2, 
[6])  
Gene amplification is a frequent finding in cancer cells. The amplification can be related 
to endo-replication leading to an increase of all or parts of chromosomes (for example 
trisomy 13 or isochromosome 6p, respectively). The other form of amplification 
corresponds more to a multiplication of the amplified segment. The amplified segment 
can appear as a homogeneously staining region (HSR), which is an intra-chromosomal 
structure that is interpolated in the normal banding pattern of a regular chromosome. 
The cell can also house extra-chromosomal structures, such as double minute 
chromosomes (size ranging from 250 kb to several Mb) or episomes (size ranging from 
100 to 200 kb).  
 
1.2.2 Tumour suppressor genes 
 
In a simplistic way, a tumour suppressor gene is a gene that “prevents” formation of a 
cancer. The prototype tumour suppressor is the retinoblastoma gene, RB1, which is 
inactivated in the childhood tumour retinoblastoma. From a statistical analysis of the 
clinical manifestation of this tumour, Alfred Knudson inferred the two-step mutation 
hypothesis [10]. The hypothesis has laid the fundament of the tumour suppressor gene 
concept. In general this concept assumes that a cell that is defective in only one of its 
two alleles behaves as a normal cell, i.e. there is no loss of control until both gene copies 
are put out of action. However, loss-of-function of one allele may enhance the 
susceptibility to cancer. The first as well as the second allele may be lost by a 
chromosomal deletion, inactivated by a point mutation or via epigenetic silencing. The 
second copy is usually lost by a less specific mechanism: the chromosome carrying the 
remaining normal allele may be lost from the cell by a variety of chromosomal 
mechanisms such as mitotic recombination or may be replaced by the mutant allele 
through gene conversion (Fig 1-2).  
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Fig. 1-2. Chromosomal mechanisms leading to loss of heterozygosity of 
chromosome 13 in retinoblastoma. In hereditary retinoblastoma, one 
germline mutation and one somatic mutation occurs. In non hereditary 
retinoblastoma, two somatic mutations occur. I: non disjunction, II: non 
disjunction with duplication of the chromosome, III: mitotic 
recombination, IV: local mutation. rb, mutant RB1 allele; + wild-type 
RB1 allele; (A and B) (alleles 1 and 2) are polymorphic loci proximal and 
distal of the RB1 allele (adapted from Cavenee et al. 1983). 
 
1.2.3 Stability genes 
 
As in the case of tumour suppressor genes, both alleles of stability genes (or caretakers) 
must undergo mutation in order to contribute to tumour initiation and progression. 
However, this contribution is indirect because inactivation of stability genes does not 
directly promote growth of tumours. Rather, the resulting genetic instability causes an 
increased mutation rate that in turn promotes clonal evolution. Stability genes are 
involved in mismatch repair (MMR), nucleotide-excision repair (NER) and base-
excision repair (BER).  
 
1.3 Retinoblastoma 
 
Retinoblastoma is the most common intraocular malignancy in children with an 
incidence of 1 in 15.000 – 20.000 newborns [7-9].  
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The observation of a leukokoria (a white reflection in the pupil) is often the first sign of 
retinoblastoma, some patients can also show strabismus. Glaucoma, uveitis or blood in 
the vitreous are rarely the first symptoms but can appear in later stages of the disease. 
The diagnosis is made by examination of the retina. In addition, ultrasound scan 
examinations, computer tomography and bone marrow puncture can also be necessary. 
The treatment chosen depends on the size, the location and the age of the patient. The 
tumour may be destroyed within the eye using cryo-coagulation, photo-coagulation or 
radiotherapy. If the tumour is big or has invaded extraocular tissues, the eye is usually 
removed (enucleation). Treatment of retinoblastoma is very effective, and the survival 
rate at 5 years is greater than 90%. However, in children with hereditary retinoblastoma, 
who have a tumour susceptibility because they are heterozygous for an oncogenic RB1 
gene mutation,  second primary neoplasms like osteosarcoma, glioma or lipoma can 
appear in adolescence and adulthood. These are a major cause of long term death of 
disease. 
 
1.3.1 Genetics of retinoblastoma 
 
Retinoblastoma initiates during retinal development as a result of RB1 inactivation in 
the developing retina. According to the Knudson’s two-hits hypothesis [10] (Fig. 1-2), 
two mutations that result in loss of function of both alleles of the tumour suppressor 
gene RB1 [11, 12] are a prerequisite for the development of both the hereditary and the 
nonhereditary form of this tumour  
• Nonhereditary retinoblastoma 
About 60% of affected children develop retinoblastoma in one eye only 
(unilateral retinoblastoma). In some of these patients, multiple tumour foci can 
be discerned (unilateral multifocal retinoblastoma). In most of these children 
(88-98%), the two mutations that are needed to inactivate both RB1 alleles have 
occurred successively in somatic cells. 
• Hereditary retinoblastoma 
The remaining 40% of children with retinoblastoma have tumours in both eyes 
(bilateral retinoblastoma) and they often show more than one focus per eye 
(bilateral multifocal). The majority of these patients are heterozygous for an 
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oncogenic RB1 gene mutation that has occurred de novo in the germ line of one 
of the parents or has been transmitted from mutation carrying parent. 
Unilateral retinoblastoma is mostly detected later than bilateral retinoblastoma. This is 
reflected in the median age of the patients at diagnosis which is 11 months for bilateral 
and 22 months for unilateral retinoblastoma. About 10% of patients with bilateral 
retinoblastoma have familial disease. Children of patients with retinoblastoma are 
regularly examined and, therefore the tumour is diagnosed at an earlier stage. 
 
1.3.2 Histopathology of retinoblastoma 
 
Retinoblastoma can present two types of growth in the eye: the endophytical type of 
growth is characterized by tumour in the vitreous (in front of the retina) and often 
presents multiple free colonies. In the exophytic type of growth the tumour fills the 
retro-retinal compartment and thrusts the retina. These two forms of growth can co-
occur in the same eye.  
The histology is characterized by the presence of rosettes and fleurettes. A rosette 
(Flexner-Wintersteiner rosette) is a group of cubic cells organized in a tube shape and 
presenting a lumen containing a vessel. The cells composing the rosettes are primitive 
photoreceptors. Fleurette is a formation in which the cells are more differentiated than in 
rosettes, they have the specific shape of photoreceptors and are arranged like the rosette 
cells around a lumen.  
The tumour appears often highly necrotic and calcified foci can be found in areas of 
necrosis. 
 
1.3.3 The origin of retinoblastoma 
 
The retina is composed of 2 parts: the retinal pigmented epithelium at the outer layer, 
and the neural retina in the inner layer [13] (Fig 1-3). The neural retina consists of 
amacrine, bipolar, Müller glia, ganglion, horizontal cells and light sensitive 
photoreceptors neurons (rods and cones); it begins to differentiate at 4-5 weeks of 
gestation. The retinal progenitor cells are multipotent and can give rise to all the cell 
types in the retina, they undergo unidirectional changes in competence. The first rods 
and cones appear in human embryos at 10-15 weeks, and the horizontal, bipolar and 
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ganglion cell layers appear in the middle of embryonic development. The retina is fully 
developed several months after birth.  
 
 
Fig 1-3. Schematic section through an adult human eye. The vertical line divides the anterior 
segment of the eye (the cornea, lens, iris and ciliary body) from the posterior segment 
(consisting mainly of the vitreous humour, retina and the choroidea). The panel on the right 
shows a close-up view of the components of the retina, which are (from the outside to the 
inside of the retina): the retinal pigmented epithelium (RPE), photoreceptor cells (rod and 
cone), Müller glial cells, bipolar cells and ganglions cells (modified from Nature Reviews 
Genetics, November 2003, Volume 4). 
 
 
The cell of origin of retinoblastoma is not clearly characterised but different models 
have been envisaged: the progenitor-cell model and the transition-cell model. 
The progenitor-cell model proposes that the earliest defect following RB1 inactivation is 
a continued division (ectopic proliferation) by a subset of progenitor cells of the retina,  
thus facilitating the appearance of post-RB mutations (additional genetic defects) 
necessary to promote transformation. The transformed progenitor cell generated has 
infinite self-renewal capacity that drives tumour growth [14].  
The second cell of origin model is the transition-cell model. The retinal transition cells 
are not multipotent and not yet fully differentiated, but they are committed to a 
particular cell type. In this model RB1 has no action on the progenitor cells but only on 
the post-mitotic transition cells, and in the absence of RB1 (inactivation of RB1) the 
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transition-cell differentiation progress uncoupled from cell cycle exit, the transition cells 
migrate to their final destination and continue to divide. 
 
1.3.4 The RB1 gene 
 
RB1 was the first tumour suppressor gene to be cloned [15]. This gene spans 180 kb on 
the long arm of chromosome 13 (13q14) and contains 27 exons. The protein is involved 
in several cellular processes with the most prominent being regulation of the cell cycle. 
For this aspect of RB1 function, the transcription factor E2F1 is an important cellular 
target. Hypophosphorylated pRb represses E2F-mediated gene transcription by 
recruiting chromatin remodelling complexes to the promoter in the resting cells. At the 
G1-S phase transition, pRb is hyperphosphorylated by CDK2, CDK4 and CDK6. 
Hyperphosphorylated pRb releases E2F, allowing it to activate transcription of its target 
genes (Fig 1-1-a). Thus, an overexpression of pRb causes cells to undergo arrest in G1 
phase of cell cycle, and cells deficient in pRb show an accelerated G1 transition. 
Oncogenic alteration of the pRb pathway can occur by mutational inactivation of the 
RB1 or CDK2 tumour suppressor genes or mutational activation of the genes encoding 
cdk4 and cyclin D1 oncogenes.  
In addition to its role in cell cycle control as a cellular proliferation inhibitor, pRb has a 
role in DNA replication [16, 17], differentiation [18] and apoptosis [18, 19]. The 
functions of pRb depend on the cellular context. For example, loss of RB1 can lead to 
increase apoptosis in some circumstances, a consequence that is paradoxical to the 
classification of the RB1 as a tumour suppressor [20]. 
 
1.3.5 Progression of retinoblastoma 
 
Much evidence indicates that the two mutational events, which result in loss of pRB 
from a developing retinal cell, are not enough for transformation into malignancy. In a 
murine model Chen et al. [21] showed that rb1 loss confers infinite proliferative 
capacity to the cells of origin of retinoblastoma, but – at the same time – renders them 
more susceptible to apoptotic cell death. This suggests that additional mutations in 
genes that regulate apoptosis are necessary for tumorigenesis to occur [20].  
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Furthermore, chromosome-banding studies [22-24] and comparative genomic 
hybridization [25-28] revealed that other genetic alterations occur during the 
development of retinoblastoma. One specific chromosomal rearrangement, 
isochromosome 6p, i(6p), is observed in 60% of retinoblastomas in cytogenetics studies. 
The presence of an i(6p) results in a low-level genomic amplification of chromosome 
6p. Usually the two normal chromosomes 6 are still present [29]. Analysis by 
fluorescent in situ hybridization with probes specific for chromosome 6 suggests that 
some retinoblastomas without cytogenetic evidence of i(6p) also may have amplification 
of regions of 6p. This suggests that i(6p) may be important for retinoblastoma formation 
[30]. Recently, CGH studies have narrowed the region of gains on 6p to the band 6p22 
[31].  
There are other recurrent genomic alterations in retinoblastoma.  These include gains on 
chromosome on 1q and 2p, and losses of 16q [32-34]. Gains on chromosome 1q have 
been detected in 40 to 50% of retinoblastomas [24-28, 35]. In one CGH study, the 
minimal region of gain on the long arm of chromosome 1 was localized to 1q31-q32 
[28], a region containing the GAC1 gene. Losses on 16q have been observed in 18 to 
46% of retinoblastomas [25-28]. Marchong et al. defined a minimal region of loss on 
chromosome 16 at 16q22. This region is known to contain a cluster of cadherin genes, 
and the results of these authors pointed to CDH11 as target of loss on chromosome 16. 
Gains of material on 2p were first observed in retinoblastoma cell line Y79 and in two 
primary retinoblastomas [36]. The amplification included the N-Myc gene, and an 
overexpression of this gene was also seen. Recently, CGH studies have shown that gains 
on 2p are present in 10 to 38% of retinoblastomas. 
 
1.4 Aims 
 
The overall aim of the present study was to identify the genes that are the functional 
targets of genetic alterations in retinoblastoma. This knowledge will provide insight into 
the biologic alterations underlying the progression of this tumour. 
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1.4.1 Chromosome 1q gains 
 
The gene(s) targeted by the alterations on chromosome 1 are currently unknown. The 
aim of the project is firstly to identify this gene(s). The region 1q31-q32 that was 
identified previously by Herzog et al. contains the GAC1 (LRRN5) gene that has been 
found to be amplified and overexpressed in malignant gliomas [37]. Next to this region 
is the MDM4 gene, which, by amplification and overexpression, contributes to the 
development of gliomas [38, 39]. However, these genes are only some of many genes 
located in the region 1q31-q32, which spans about 25 Mb. In the present study we used 
Quantitative Multiplex PCR and array CGH to identify DNA segments with genomic 
imbalances in retinoblastoma. We have determined DNA copy numbers of several loci 
in this region to identify the single gene or the set of genes that are the functional targets 
of genomic gains. We have used genome-wide RNA expression analysis to evaluate the 
expression pattern of genes located in these regions. In addition, we have obtained 
detailed data on the patient’s clinical manifestation to find out if clinical behaviour of 
tumours with genomic gains on 1q is distinct from that of tumours without gains.  
 
1.4.2 Chromosome 16q losses 
 
A previous study based on mapping of the minimal region of losses on 16q indicated 
that loss of the CDH11 gene might contribute to progression of retinoblastoma [40]. We 
have used microsatellite analysis and pyrosequencing to further localise the region of 
loss of heterozygosity. Moreover, as epigenetic inactivation of tumour suppressor genes 
is relatively frequent, we have set up a specific methylation assay for CDH11. The 
results we obtained were compared with expression of the corresponding genes. 
 
1.4.3 Chromosome 1p gains 
 
Within the course of the study, array CGH was used to determine gains and losses on a 
genomic level. The results revealed a novel region of amplification on the short arm of 
chromosome 1. We combined genomic results and expression data to analyse the 
possibility of a novel oncogene involved in progression of retinoblastoma. 
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2 MATERIAL AND METHODS 
2.1 Material 
 
Standard chemicals and solutions were obtained from Boehringer Mannheim 
(Mannheim), Merck (Darmstadt), Sigma-Aldrich (Heidelberg), Serva (Heidelberg), 
Invitrogen (Karlsruhe), and BD Biosciences (Heidelberg). 
2.1.1 Buffers, reagents and solutions 
Standard solutions for molecular genetics  
10X loading buffer:   0.25% Bromphenol blue or Xylene blue, 15% Ficoll, 10 
 mM EDTA 
Chloramphenicol solution: 34mg/ml chloramphenicol in Ethanol 100% 
LB-Medium:    1% Tryptone, 0.5% Yeast extract, 1% NaCl, 30µg/ml  
  Chloramphenicol  
LB-Plates:   LB-Medium, 1.2% Bacto-Agar (Difco), 12.5µg/ml  
  Chloramphenicol 
TAE-Buffer:   40 mM Tris-Acetat, 1 mM EDTA 
TE:   10 mM TRIS-HCL (pH 7.8), 1 mM EDTA 
Bisulfite solution: for a final volume of 20 ml, 8.5 g sodium bisulfite is 
diluted in 15 ml H2O under N2 gas. The solution is then 
put on a rolling machine to assist complete dissolving. To 
complete the solution 0.9 ml hydrochinon at 50 mM and 1 
ml 10N NaOH pH 5.0-5.3 are then added.  
 Note: the bisulfite solution is light sensitive and, therefore, 
must be kept in darkness during the preparation and use 
for treatment of DNA. 
Solutions and reagents for Matrix-CGH 
20X SSC:   3M NaCl, 0.3 NaCitrat 
Wash A:   50% Formamid, 2X SSC, pH 7.0 
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PN Buffer:    0.1M Na2HPO4, 0.1% nonidet P40 (USB Corporation,  
    Cleveland), pH 8.0 
2.1.2 Enzymes 
 
AmpliTaq® DNA polymerase (5 U/µl):   Applied Biosystem, Darmstadt 
AmpliTaq® Gold DNA polymerase (5U/µl):  Applied Biosystem 
PCR Multiplex kit:   QIAgen, Hilden 
Desoxyribonuclease I (DNase I) (3 U/µl):  Qiagen, Hilden 
DNA Polymerase I, Klenow-Fragment (0.5 U/µl): Boehringer, Mannheim 
Proteinase K (10 µg/ml):   Boehringer, Mannheim 
2.1.3 Oligonucleotide arrays 
 
HG-U133A GeneChip® Arrays from Affymetrix Inc. (Santa Barbara, CA) were used for 
microarray hybridization analysis of RNA expression.  
2.1.4 Primary tumours  
 
Samples of retinoblastomas were obtained at the time of operative treatment, snap 
frozen in liquid nitrogen, and stored at -80°C.  Prior to use for research, mutation 
analysis of the RB1 gene was performed as part of a routine genetic service. Material 
from patients with resolved mutational status of the RB1 gene was used for the present 
study. In addition, two primary gliomas were also used in the present study (both 
samples provided by Prof. G. Reifenberger, University of Düsseldorf). 
2.1.5 Cell lines 
 
Material from 6 retinoblastoma cell lines was investigated: WERI-Rb1 [41], Y 79 [42], 
RBL 30, RB 247C3, RB 355 and RB 383 [43]. We also analyzed DNA from a uveal 
melanoma cell line (Mel202, provided by G. Anastassiou and M. Zeschnigk). 
2.1.6 Clones 
 
Recombinant DNA cloned in Bacterial Artificial Chromosomes (BAC) was obtained at 
the RessourcenZentrum/Primär Datenbank (RZPD), Berlin (Table 2-1). 
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Table 2-1. BAC clones used on Matrix-CGH slides specific for chromosome 1 
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2.1.7 Primers and Probes 
 
Sequences of oligonucleotide primers for PCR and sequencing were chosen using the 
Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), data 
available through databases at the NCBI (http://www.ncbi.nlm.nih.gov/), Primer 
Express software (version 2.0; ABI) for the Real Time PCR, and the DNASTAR 
software package (DNASTAR, Madison, WI, USA). All forward primers used in 
Quantitative Multiplex PCR were labelled with a 6-FAM fluorescent dye. 
DNA oligonucleotides were custom synthesized by different companies: Biomers, Ulm, 
Germany; Applied Biosystems, Darmstadt, Germany; and Eurogentec, Seraing, 
Belgium. 
 
2.1.8 Equipment 
 
PCR Machines: GeneAmp® PCR System 9700 (Applied Biosystems) 
    GeneAmp® PCR System 2700 (Applied Biosystems) 
    Peltier Thermal Cycler 200 (MJ Research) 
Capillary electrophoresis for sequencing and microsatellite analysis:  
ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA)  
Real-Time quantitative PCR, TaqMan®: ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems) 
PyrosequencingTM machine: PSQTMHS 96A System, PyrosequencingTM Vacuum Prep 
Workstation (Uppsala, Sweden) 
 
2.2 Methods 
2.2.1 Cell culture 
 
Culture of retinoblastoma cell lines was performed by Harald Stephan at the Children’s 
Hospital (Div. of Haematology and Oncology), University of Duisburg-Essen. Cell lines 
were cultivated in DMEM with 15% foetal calf serum, 100 U Penicillin/ml, 100 µg 
streptomycin/ml, 4 mM L-glutamine, 50 µM ethandiol and 10 µg insulin/ml at 37°C, 
10% CO2 and 80% humidity. 
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2.2.2 DNA extraction from blood samples 
 
Genomic DNA was extracted from peripheral blood using the Nucleon BACC2-Kit 
(Amersham LIFE SCIENCE) according to the protocol supplied. In brief, 2 to 5 ml 
blood is collected and mixed up with 40 ml reagent A for 4 min on a rotating device. 
Leucocytes pellets are formed by centrifugation for 4 min at 3,500 rpm at room 
temperature (RT), and the supernatant is discarded. Reagent B (2 ml) is added to 
resuspend the pellet. Sodium perchlorate solution (500 µl) is added and after 20 min in 
an agitating water bath at 65°C, protein is removed and DNA extracted by mixing with 
2 ml cold chloroform. Phases are separated by centrifuging for 1 min at 3,000 rpm. 
Without remixing the phases, 300 µl Nucleon resin is added to the tubes and spun down 
for 3 min at 3,500 rpm. The phase above the Nucleon resin layer, which contains the 
DNA, is transferred to a clean tube and spun down for 3 min at 3,500 rpm. DNA is 
precipitated from the supernatant in a fresh tube with 4 ml of cold absolute ethanol. The 
precipitate appears after mixing by inversion. The DNA is removed with a melted tip of 
a Pasteur pipette, washed in 70% ethanol, dried in the air for 15 min and dissolved in TE 
buffer on a rolling device for about 2 days.  
 
2.2.3 DNA extraction from tumour samples 
 
The tumour sample is homogenized in a glass homogenisator or using a Pasteur pipette 
in 250 µl of 75 mM NaCl/24 mM EDTA/10mM Tris HCl pH 8 and transferred in a 1.5 
ml tube. After addition of 250 µl of 75 mM NaCl/24 mM EDTA, 25 µl 10% SDS and 
10 µl Proteinase K (10 mg/ml) the mix is vortexed and incubated for 4 hours at 37°C in 
a water bath or on a rotating thermomixer (850 rpm). Phenol (300 µl) is added, mixed, 
and the sample is spun down 3-5 min at 13,000 rpm. The aqueous (upper) phase is 
collected with a pipette and transferred in a new tube. After adding 300 µl of 
chloroform/isoamylalcohol (96% CHCl3/ 4% IAA) the solution is well shaken and 
centrifuged 3-5 min at 13,000 rpm. The last two steps have to be repeated 2 times. Next, 
the upper phase is transferred to a new tube, and 50 µl NaOAc and 900 µl 100% ethanol 
are added. The DNA precipitates from the solution after inverting the tube. The DNA is 
removed, washed in 70% ethanol, 15 min dried in the air, and dissolved in TE buffer (on 
a rolling device for about 2 days). 
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2.2.4 DNA extraction from BAC clones 
 
Bacteria are grown in LB medium (with 30 µg/ml Chloramphenicol) overnight in a 
shaking incubator (New Brunswick Scientific G26) at 37°C and 275 rpm. For DNA 
extraction we adapted the QIAgen Plasmid Purification protocol. The first steps of 
preparation from buffer P1 to P3 are identical to the original protocol from QIAgen. 
For preparation of analytic DNA amounts (“mini-preparation”) a bacterial colony is 
incubated overnight in 5 ml LB medium. 1.5 ml of the overnight culture is centrifuged 3 
min at 5,000 rpm and the pellet is taken in 300 µl Buffer P1 (50 mM Tris HCl pH 8.0, 
10 mM EDTA ph 8.0, 100 µg/ml RNase A). After the addition of 300 µl Buffer P2 (200 
mM NaOH, 1% SDS) the mix is incubated for 3 min at RT. 300 µl Buffer P3 (3M 
KOAc pH 5.5) are added and spun down 15 min at 10,000 rpm and 4°C. The 
supernatant is taken out, 500 µl 100% ethanol is added and, after inversion, the tube is 
centrifuged for 25 min at 13,000 rpm and RT to precipitate the DNA. The pellet is 
washed with 70% ethanol, dried and dissolved in 20 µl RNase solution (50 µg/ml 
RNaseA, 20 Units RNase T1 in H2O) and incubated 1 hour at 37°C. 
To extract large scale amounts of BAC-DNA (“maxi-preparation”), 900 µl of the 
overnight culture is incubated in 150 ml LB medium, overnight at 37°C and 275 rpm. 
The cells are harvested by centrifugation for 20 min, 4,500 rpm and RT, and the pellet 
resuspended in 20 ml Buffer P1. 20 ml Buffer P2 is added and the mix is incubated for 3 
min at RT. Chilled Buffer P3 (20 ml) is added, the suspension is incubated for 15 min 
on ice, and centrifuged for 30 min at 10,000 rpm and 4°C. The supernatant is removed 
and centrifuged again for 15 min at 10,000 rpm and 4°C. The supernatant is applied to 
the QIAGEN-tip 500 (equilibrated before with Buffer QBT: 750 mM NaCl, 50 mM 
MOPS pH 7.0, 15% ethanol, 0.15% TritonX-100). After all the supernatant has flowed 
through, the column is washed 2 times with 30 ml Buffer QC (1 M NaCl, 50mM MOPS 
pH 7.0, 15% ethanol). The DNA is finally eluted with 5 ml hot Buffer QF (1.25 M 
NaCl, 50 mM Tris-HCl pH 8.5, 15% ethanol). The DNA is precipitated by adding 3.5 
ml isopropanol, mixed and centrifuged at 10,000 rpm for 30 min and at 4°C. The DNA 
is washed with 70% ethanol, air-dried, dissolved in 100µl RNase solution and incubated 
for 1 hour at 37°C. 
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2.2.5 Restriction cleavage of DNA 
 
For enzymatic digestion, 2 µg of BAC DNA are used. The DNA is mixed with 10 to 20 
Units restriction enzyme and restriction buffer concentrate in a total volume of 20 µl. 
The restriction enzyme is stabilized by adding 0.1 µg/µl BSA. A complete cleavage of 
BAC DNA is reached 2 to 3 hours after begin of the reaction. The results of digestion 
are then determined by electrophoresis in 1% agarose gels.  
 
2.2.6 RNA extraction from tumour samples 
 
The protocol of RNA extraction is an adaptation of the QIAgen RNeasy Mini Protocol 
for Isolation of Total RNA from animal tissues (QIAgen, Hilden, Germany). All the 
buffers and columns that are contained in this kit are used excepted when specified. A 
30 µg tumour sample is placed in 800 µl Buffer RLT (ß-ME 10µl/ml, Sigma-Aldrich, 
Taufkirchen, Germany) in a Lysing Matrix D column (Q.BIOgene, Heidelberg, 
Germany) and grinded in the Lysing Matrix for 45 s at 6.5 (Fast Prep, FP 120, Bio 101 
Systems, Q.BIOgene). Dry ice is used to cool down the sample after grinding. At room 
temperature, the samples are shaken, vortexed and spun down for 5 min at 13,000 rpm 
at 4°C. The supernatant is taken out and placed in a new 1.5 ml tube, and spun down 
again in the same conditions as before. Leaving the protein pellet intact, the supernatant 
is placed in a 1.5 ml tube to which 750 µl Ethanol 70% is added, and then vortexed. The 
1.5 ml solution obtained in this step is then placed on an RNeasy mini spin column and 
centrifuged for 15 s at 10,000 rpm at 4°C (in 2 steps). The flow-through is discarded. 
Digestion with DNaseI (QIAgen) is used to avoid the presence of DNA in the final 
extract. For this, 350 µl Buffer RW1 is added to the spin column and centrifuged for 15 
s at 10,000 rpm. The flow-through is discarded. A mix of 10 µl DNaseI stock solution 
and 70 µl buffer RDD is thoroughly pipetted on the membrane of the column and 
incubated for 15 min at room temperature. After adding 350 µl buffer RW1 the column 
is centrifuged for 15 s at 10,000 rpm. The column is then placed on a new collection 
tube, 500 µl buffer RPE (with Ethanol) is added and spun down for 2 min at 13,000 
rpm. The column placed on a new collection tube and the RNA is eluted with 50 µl 
RNase free water by centrifugation for 1 min at 10,000 rpm. The elution step is repeated 
one time.  
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2.2.7 DNA bisulfite treatment 
 
Sodium bisulfite treatment modifies DNA by converting unmethylated, but not 
methylated, cytosines to uracil (see example below): 
 
Methylated      Unmethylated  
(Cytosine in CpG) 
 
5’-ACGTCAGCCG-3’     5’-ACGTCAGCCG-3’ 
  
Bisulfite  
treatment 
 
5’-ACGTTAGTCG-3’     5’-ATGTTAGTTG-3’ 
 
 
Genomic DNA (2µg/50µl) is mixed up with 5.5 µl 3M NaOH, incubated 15 min at 
37°C, denatured 2 min at 95°C and placed on ice. As a positive control we also treated 
methylated DNA (2µg/50µl Q-BIOgene, CpGenomeTM Universal Methylated DNA). 
The denatured DNA (55 µl) is then mixed with 500 µl of bisulfite solution overnight at 
50°C in darkness. The bisulfite is then removed with the Wizard® DNA Clean-Up kit 
(Promega Corporation, Madison, USA) using a vacuum manifold. The treated DNA is 
mixed with 1 ml Wizard® DNA Clean-Up Resin, and pipetted into the syringe barrel 
put on a minicolumn connected to the vacuum. The vacuum is applied to draw the 
solution in the minicolumn and is then broken. The column is washed with 2 ml 80% 
isopropanol and the help of the vacuum (the vacuum can be applied 30 s longer after the 
solution has been pulled through the minicolumn to dry the resin). The column is 
transferred to a 1.5 ml tube, centrifuged 2 min at 10,000 rpm, placed on a new 1.5 ml 
tube and eluted with 50 µl H2O (65°C) incubated 1 min and centrifuged 20 min at 
13,000 rpm. If necessary, the concentration of the DNA is increased by reconcentration 
(see below). Bisulfite treated DNA is used as a template for Methylation Specific PCR 
(MSP).  
 
2.2.8 Reconcentration of the DNA/RNA eluates 
 
DNA eluate is mixed with 5.5 µl 3M NaOH and incubated for 15 min at 37°C. After 
addition of 55 µl 6M NH4OAc pH 7, 1 µl Glycogen (5 mg/ml, Roche, Mannheim, 
Germany) and 350 µl 100% ethanol is mixed and centrifuged for 20 min at 13,000 rpm. 
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The DNA pellet is washed with 300 µl 70% ethanol and again centrifuged for 5 min at 
13,000 rpm. After the removal of the supernatant, the pellet is dried in a SpeedVac 
(SpeedVac Concentrator, Bachofer, Reutlingen) for 7 min with heating. The DNA is 
finally resuspended in 30 µl H2O. 
RNA eluates of individual sample preparations are pooled together. Glycogen (1 µl at 5 
mg/ml, Roche), 3M NaOAc pH 5.2 (1/10 Vol., Sigma-Aldrich) and Ethanol 100% (2.5 
Vol.) are added. The RNA is precipitated at -20°C for at least 1 hour and pelleted by 
centrifugating for 20 min at 4°C at 13,000 rpm. The supernatant is removed and the 
RNA pellet is washed with Ethanol 75% and again centrifuged 2-3 min at 4°C at 13,000 
rpm. The washing step is repeated 2 times. The pellet is dried on a thermoblock at 30°C 
(Thermomixer comfort, Eppendorf, Hamburg, Germany) for 5 to 10 min. The pellets are 
finally dissolved in water for 20 min on ice. The RNA is stored at –80°C. 
 
2.2.9 Measurement of DNA and RNA concentration 
 
The DNA and RNA probes are diluted in water and light absorption at 260 and 280 nm 
is determined in a spectral photometer Ultrospec III (Pharmacia). An absorbance of 1 at 
260 nm (OD260) corresponds to 50 µg/ml double stranded DNA, 33 µg/ml simple 
stranded DNA, and 40 µg/ml RNA. Therefore, the OD260 is multiplied with the factor 50 
or 40 and the dilution factor to obtain the nucleic acid concentration in µg/ml for DNA 
or RNA, respectively. The quotient OD260/OD280 is determined to estimate the 
proportion of protein contamination in the solution. A DNA solution that is protein-free 
has a quotient of 1.8 and the corresponding value for RNA is between 1.8 and 2.1. 
 
2.2.10 PCR analyses (with and without labelled primers) 
 
The reactions are carried out and modified according to the work of Saiki et al. [44] and 
Mullis und Faloona [45]. As polymerase the thermostabile AmpliTaqGold® DNA 
Polymerase (Applied Biosystems) was used. Reactions were performed in 20 µl reaction 
volume tubes or in 96 wells “optical plates” (Applied Biosystems). The final reaction 
mix (20 µl) contained 1 Unit AmpliTaqGold®-Polymerase (5 U/µl), 1 mM MgCl2 (0.8 µl 
at 25 mM), 0.5 µM of each 5’- and 3’ primer (1 µl of a primer mix at 10 µM), dNTPs 
(each at 1.25 mM), 1X reaction buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.001% 
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Gelatine; 2 µl) and 50 ng DNA. The thermal profile of the reaction was as follows: 
initial denaturation and polymerase activation for 10 min at 95°C was followed by 35 
cycles of denaturation (25 s, 95°C), annealing (30 s, at the appropriate temperature for 
each primer pair) and elongation (30 s, 72°C). Subsequently an extended synthesis time 
of 7 min at 72°C was added to reduce the variation introduced by nontemplate 
nucleotide addition. Control reactions without DNA were performed in each set of 
PCRs. 
 
2.2.11 Methylation Specific PCR (MS-PCR) 
 
Two PCR reactions are performed for each DNA sample. One is specific for methylated 
CDH11 alleles, and one specific for unmethylated alleles. This specificity is provided by 
the primer pair sequences that hybridize to the target sequences corresponding to 
bisulfite treated methylated and unmethylated alleles (Table 2-2). The PCR mixture 
contained 3.5 Unit AmpliTaqGold®-Polymerase (5 U/µl), 1X reaction buffer (50 mM 
KCl, 10 mM Tris-HCl (pH 8.3), 0.001% Gelatine; 2 µl), dNTPs (each at 1.25 mM), 1.25 
mM MgCl2 (1µl at 25 mM), 1 µM primer of each primer (1 µl of a primer mix at 
20µM), and bisulfite-modified DNA (~150 ng) in a final volume of 20 µl. The PCR 
reactions were conducted as mentioned before, with an annealing temperature specific 
for each primer pair. Controls without DNA and with bisulfite treated artificially 
methylated DNA were performed in each set of PCRs. 
 
2.2.12 Quantitative Multiplex PCR (QMPCR) 
 
Our methodology for QMPCR is based on the protocol that was developed by the group 
of B. Gallie [31] for deletion analysis of the RB1 gene. We established multiplex 
reaction sets to determine relative DNA copy numbers of 30 loci on chromosome 1q 
(Table2-3). Two control targets located on chromosome 6 and chromosome 10 were 
included in each set. Sequences of primer pairs were chosen using the Primer3 program 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and data available through 
databases at the NCBI (http://www.ncbi.nlm.nih.gov/). All forward primers were 
labelled with a 6-FAM fluorescent dye (Biomers, Ulm, Germany). For multiplex PCR, 
the QIAgen Multiplex PCR kit was used (QIAgen, Hilden, Germany). Individual 
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reactions contained 12,5 µl QIAgen reaction mix, 2,5 µl primer mix (each primer at 
1,75µM) and 150 ng DNA in a final volume of 25 µl. Cycling was performed in a 
GeneAmp PCR System 2700 (Applied Biosystems, Foster City, CA, USA) with a 
denaturation step of 15 min at 94°C; 19 cycles of denaturation (30 s at 94°C), annealing 
(90 s at 58°C or 60°C), extension (90 s at 72°C); and a final extension step at 72°C for 
10 min. Only 19 cycles were used to stay in the exponential phase of amplification, 
which is a prerequisite for comparative quantification.  
 
Calculation of relative copy number  
 
For normalization of values, peak areas of each product within one QMPCR were 
divided by the peak area of the control locus on chromosome 10q obtained in the same 
reaction. To determine the relative DNA copy number for each locus, normalized peak 
integrals were compared to the mean of the values obtained in normal control DNA 
(constitutional DNA from 5 healthy individuals, Fig. 2-1). Numerical processing of 
QMPCR data was performed with Excel 2000 (Microsoft). According to this algorithm, 
a value of ‘1’ was obtained for loci with a DNA copy number of 2. As a control we 
investigated the uveal melanoma cell line, Mel 202, which has 3 copies of the entire 
chromosome 1 as determined by cytogenetics analysis (Nareyeck G., Zeschnigk M. et 
al. manuscript under revision). The corresponding DNA copy number value was 1.5. 
We validated our methodology by analysis of DNAs from gliomas with known 
amplification of a region in 1q that includes the MDM4 gene [38, 39]. For subsequent 
evaluation by Significance Analysis of Microarrays (cf. “Expression analysis”) and 
comparisons with CGH data, samples were considered to have gains of material of the 
1q32 region if more than one marker in this region showed a value equal or higher than 
1.5.   
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Table 2-3. Loci analysed by QMPCR (NCBI database) 
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2.2.13 Quantitative Microsatellite Analysis Real Time PCR: QuMA 
 
We assessed the DNA copy number at 3 loci using the quantitative real-time PCR assay 
described by Ginzinger et al. [46], Fig 2-2. The QuMA technique allows analysis of 
allelic imbalance that result in loss or gain of a single copy of a gene; it determines 
DNA copy numbers by Real time PCR using Taqman probes specific for CA-repeat 
motifs. We selected 3 microsatellite loci: D1S2668 (centromeric to REN gene), D1S504 
(contained in GAC1 gene) and D10S548 (control located on chromosome 10, known to 
have no genetic alterations in retinoblastoma by means of CGH).  
An additional primer pair and specific probe were designed for the MDM4 gene in the 
exon 10, as no microsatellite was available in this gene. As reference for MDM4 we 
used AS-SRO gene product located on chromosome 15.  The primers and probes were 
designed using the Primer Express software (version 2.0; ABI). Quantitative Real-Time 
PCRs were performed in a 25µl volume reaction containing 50 ng of DNA, 12,5 µl 
1×TaqMan Universal PCR Master Mix, 300 nM of each primer and 250 nM of the 
TaqMan probe (ABI, Foster City, Calif.). Cycling was performed with 2 min at 50°C 
and 10 min at 95°C for denaturation and activation of the polymerase, and 40 cycles 
with a step at 95°C for 15 sec (denaturation) and a step at 60°C for 1 min (annealing).  
The primer sequences used are as follow:  
 
Table 2-4. Sequences of probes and primer pairs used in Real Time PCR. 
  Sequence Gene 
CA-repeat probe VIC-TGTGTGTGTGTGTGTGTGT-MGB   
D1S504-R AAGGTTACATGGAGCCGTGTGT GAC1 
D1S504-F GTTGAAGGTCAAAGTGTGGAAA   
D10S548-R CTGCTCATAATCTTGGTTGTG Control on 
D10S548-F TATTGAGGTATAGGGACAGGG chromosome 10 
D1S2668-R ACTGACTGGCTGTTTCTGAG REN 
D1S2668-F AATCACTTGAACCTGGGAG   
MDM4-R CGACAGGAGCCGAAATGGT  
MDM4-F TCACTGCCATACCTGAAAAGGA  
MDM4 probe 6FAM-AAGAAGGAAATGATGTCCCTGATTGTCGAAG-TAMRA   
AS-SRO-F GCTCCATCCCAGGGTTTCTAAT Control on 
AS-SRO-R GCACTTGTTCGAAATGCAGATT chromosome 15 
AS-SRO probe FAM-TCAGGGTTTGGTTTGCGGCAGAA-MGB   
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PCR was carried out using the ABI Prism 7000 Sequence Detection System (ABI). All 
reactions were performed in duplicate. Standard curves for all 10 assays were performed 
with 125 ng, 100 ng, 50 ng, 25 ng and 12.5 ng of DNA. As the efficiencies of all the 
PCR we not equal we couldn’t use the Comparative CT method, therefore we performed 
quantification using the standard curve method, with a control on chromosome 10 or 
AS-SRO as calibrators. We calculated the N value (ratio of the copy number of target 
gene to the copy number of reference gene, [47]) for each of the genes.  
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2.2.14 MSA for LOH study 
 
For microsatellite analysis (MSA) 10 polymorphic microsatellite loci, all dinucleotide 
repeats (CA)n were chosen. To identify allele loss on the long arm of chromosome 16 
the genotype of constitutional cells was compared to that obtained from DNA of tumour 
cells. We analyzed 2 loci on the short arm of chromosome 16, and 8 on 16q (2 in the 
centromeric region, 2 in the telomeric region, and 4 in the minimal region of loss 16q22, 
Table 2-5). 
PCR was performed in two multiplex reactions each containing primer pairs for 5 
products. The concentrations of the primers were adjusted to obtain balanced signals in 
the ABI PRISM® 3100 Genetic Analyzer. For the multiplex PCR, the QIAgen Multiplex 
PCR kit was used (QIAgen, Hilden, Germany) and the PCR protocol used was the same 
as for QMPCR (with an annealing temperature of 58°C). 
 
Table 2-5. Loci analysed by MSA. The forward primer was labelled (FAM, PET or NED) 
 
Location and 
Position (bp) 
Name 
Primer Sequence (Forward 
and Reverse) 
PCR set C° µM Size bp 
16p D16S3093 FAM-gaaacaagggcaaaactcca 2 1.75 237 
    gaataaagggaaggtacacctacat    
16p D16S3068 FAM-ccctgtagcaaaatttcacc 2 1.75 104 
    ccgccacagtaaagattagg    
16q D16S409 PET-tgtgaatcttacatcccatcc 1 1.8 150 
47333372    agcttttagagtcagtctgtcca    
16q D16S3080 PET-ggatgcctgctctaaataccc 1 2.1 179 
48240903    cccaggggtcaaacttaatc    
CDH11 D16S3050 NED-acagggtaatcgttcttcca 1 1.75 189 
63624548    gcaaactggcttgtgatttc    
CDH5 D16S421 FAM-acacatgaaccgattggact 1 1.6 225 
65853212    ttaacatgttcctccgttcc    
  D16S3085  NED-ctgggtgacagaacaagacc 2 1.75 190 
66225096    caggacactaagccggaaat    
CDH3 D16S3025  FAM-tccattggacttataaccatgc 1 1.5 100 
67123897    gagacatctggggacaagaa    
16q D16S3074 PET-acatgtgctcaccaacacac 2 1.75 174 
85642280    ttgggtttccaaagtcagtc    
16q D16S3048 PET-tcggaggatcactggaagt 2 1.75 280 
85862067    gtagtgtcctgggggatttc     
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2.2.15 Electrophoresis and analysis 
2.2.15.1 Agarose Gel electrophoresis 
 
To verify the efficiency and specificity and to estimate the amount of DNA (BAC DNA) 
electrophoresis was performed in gels containing 1-3% agarose. Agarose powder was 
cooked in 1x TAE buffer, cooled down to 65°C. After adding 0.4 ∝g/ml Ethidium 
bromide the solution was poured in gel trays. From a 20 µl PCR reaction, 5 µl were 
loaded on the gel. The probes were previously mixed with loading buffer (end 
concentration 1x), and separated by applying a 3 V/cm field in 1x TAE Buffer 
containing 0.4 ∝g/ml Ethidium bromid. Different size standard were used: 1 kb ladder 
(Invitrogen), MspI-splitted pUC19 DNA (MBI Fermentas, St.Leon-Roth) und HindIII-
cut Lambda-DNA (Boehringer). Stained DNA was visualized with a UV-light 
transilluminator (302 nm) and documented on thermosensitive paper with a digital 
photo-system (Herolab, Wiesloch).  
 
2.2.15.2 Automatic Capillary Electrophoresis (Genescan and Sequencing) 
 
Automatic electrophoresis and multi-colour fluorescence-based DNA detection was 
performed with a 16 capillary analysis system (ABI PRISM® 3100 Genetic Analyser, 
Applied Biosystems). The recommended polymer (POP-6™, Applied Biosystems) was 
used for separation. In this analysis system the DNA fragments are separated according 
to their size. The fluorescence labels attached to the fragments are detected by a 
stationary unit consisting of a laser (for fluorescence excitation), a mirror for spectral 
separation, and a CCD camera that converts the luminescence signal into digital data 
treated by the software. Like in a conventional electrophoresis and pass at the same time 
a laser beam where the attached fluorochrome is excited, the fluorochrome emits a light 
with a wave length specific to the dye. The light is collected and detected by a 
spectrophotometer. When using different fluorescent dyes, several PCR products can be 
mixed and analysed in one capillary. A size standard is mixed with each PCR product to 
get a precise size value of the DNA fragments analysed (GeneScan™-500, Applied 
Biosystems with 6-Carboxy-X-Rhodamin, 6-ROX™, or 500 LIZ®). For size 
determination of the fragments and quantification we used GeneScan™ und Genotyper® 
(Applied Biosystems). Sequencher (Gene Codes Corporation, Ann Arbor, MI, USA) 
was used for sequence analysis. 
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2.2.15.3 DNA sequencing 
 
The BAC DNA was sequenced with primers T7A (5’-
CGGTCGAGCTTGACATTGTA) and SP6A (5’-CGATCCTCCCGAATTGACTA). 
These primers are not the originally T7 and SP6 primers, but are located in the same 
region. They have a higher Tm (60°C) to increase specificity of the sequencing reaction. 
For some BACs specific primers were selected to verify the results obtained with the 
usual T7 and SP6 primers (Table 2-6). The sequencing reaction mixture contained 2 µg 
DNA, 10 pmol primer, Big dyeTM (8 µl, according to the manufacturer’s 
recommendation, Applied Biosystems) in a total volume of 20 µl. BAC DNA was 
sonicated before the sequencing reaction to improve annealing of the primer. The cycle 
sequencing reaction was performed with 5 min at 95°C, 50 cycles of 30 sec at 95°C, 10 
sec at 60°C and 4 min at 60°C. The products of sequencing reaction obtained were 
precipitated. For this the reaction volume was completed with water to a final volume of 
100 µl (add 80 µl). The solution was then mixed with Dextran blue (2 µl REF), NaOAc 
3M (10 µl) and 100% ethanol (250 µl), vortexed, centrifuged 15 min at 13,000 rpm. The 
pellet was washed with 70% ethanol two times and then dried in a SpeedVac. The DNA 
pellet was dissolved in 20 µl formamide for electroinjection in an ABI PRISM® 3100 
Genetic Analyser. The analysis of the results has been made with the software 
“Sequencher” from Gene Codes Corporation, Ann Arbor, MI, USA. 
 
Table 2-6. Sequencing primers specific for BAC clones 
BAC clone Sequencing primer  
RP11-184F4 TGTTCTCCTGGGTTCCAGTT 
RP11-69I9 ACTATAGGGATGGCGTCTGC 
RP11-348A7 ATGAGCCAGCTCCTGAATCT 
RP11-203F10 GATGTCACCAGGACACTCCA 
RP11-75I2 CAGGAATGCACTCCACACAC 
RP11-207I9 ATGATGGTAACTGCGTGCAA 
RP11-454L1 GCAACGTGGAACTATGAGGTG 
RP11-108M21 TCAATCTCTTGCCCTTGTGA 
RP11-164O23 GACATTCAAGAACAGAAAAGCAG 
 
 
2.2.15.4 Genotyping of STR loci for identification of LOH on chromosome 16 
 
For analysis of the PCR products obtained in QMPCR, 1 µl of the PCR products were 
added to 12 µl of deionised formamide containing 1 µl of ROX fluorescently labelled 
GeneScan-500 size standard (Applied Biosystems). Signals were evaluated using 
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GeneScan and Genotyper software (Applied Biosystems). QMPCR products obtained 
from constitutional DNAs from 5 healthy persons were included as controls for normal 
copy numbers. 
For the analysis of the PCR products obtained in the multiplex PCR of STR loci, 0.8µl 
of the PCR products were diluted to 2 µl and added to 12 µl of deionised formamide and 
1 µl of LYS fluorescently labelled GeneScan-500 size standard (Applied Biosystems). 
Analysis was performed using an ABI PRISM® 3100 Genetic Analyser and results were 
evaluated using GeneScan and Genotyper software (Applied Biosystems). 
 
2.2.16 Pyrosequencing (PSQ) 
 
This method is usually used to perform DNA sequence information for genotyping of 
Single Nucleotide Polymorphism (SNP), microbial typing, resequencing (for review see 
Ronaghi M. [48]). Here, PSQ was used for relative quantification of alleles of SNP loci 
that are located in genes that were also investigated by QMPCR. Relative quantification 
is possible for tumours from patients that are heterozygous for a SNP to be analyzed 
[49, 50]. The SNPs analyzed here and sequences of primers used are listed in Table 2-7. 
Primer sequences were chosen using “Primer3Input” and the NCBI SNP database.  
We also used PSQ to investigate the loss of heterozygosity (LOH) on chromosome 16. 
In this case the patients that were heterozygous for a SNP in blood DNA were seen as 
homozygous in tumour when LOH was present. The primers used are listed in Table 2-
8. 
PSQ was performed using the PSQ96 Sample Prep Tool and the PSQ96 SNP reagent kit 
according to the manufacturer’s instructions (Pyrosequencing AB, Uppsala, Sweden). 
Briefly, template for PSQ is prepared in a conventional  50 µl PCR reaction (reaction 
mix: 1 Unit AmpliTaqGold®-Polymerase (5 U/µl), 2.5 mM MgCl2 (5 µl at 25 mM), 0.5 
µM of each 5’- and 3’ primer (1 µl of a primer mix at 10 µM), dNTPs (each at 1.25 
mM), 1X reaction buffer (50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.001% Gelatine; 2 
µl) and in general 160 to 400 ng DNA). From the PCR product 40 µl are pipetted on a 
PCR microtiter-plate, and mixed with binding-buffer/streptavidin coated Sepharose 
beads master mix (37 µl/3 µl). The PCR microtiter-plate is thoroughly mixed on a 
microtiter-plate shaker for 10 min. Concurrently 1.5 µl sequencing primer at 10 µM and 
43.5 µl annealing-buffer are pipetted in each slot of the PSQ plate. After applying 
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vacuum at the workstation, the beads with immobilized PCR product are picked up by 
the Vacuum Prep Tool from the PCR plate and transferred to a separate trough 
containing 70% ethanol. After ethanol was aspirated through the filter probes, the 
Vacuum Prep Tool is placed in another trough containing sodium hydroxide (NaOH 
0.2M). With the vacuum still on, the DNA is denatured and the single-stranded DNA 
released and removed. The 5’-biotinylated strands remain immobilized on the bead. 
Next, the tool is placed in a trough containing wash buffer and the immobilized DNA is 
rinsed by aspiration. The single-stranded templates are then transferred to the PSQ plate 
containing annealing buffer and primer. After release of the vacuum, a gentle shake of 
the Vacuum Prep Tool releases the beads with templates attached into the 96-well PSQ 
plate. After annealing the sequencing primer (80°C, 2 min) this plate is ready for 
analysis using a Pyrosequencing System. The program PSQ96 evaluation AQ was used 
to determine allele signal heights in PCR products from blood DNA and tumour DNA. 
The signal ratio of allele 1 to allele 2 in PCR products from blood DNA of heterozygous 
patients was used for normalization of the signal ratios obtained in DNA from 
corresponding tumours (example in Fig. 2-3).  
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2.2.17 Comparative Genomic Hybridization 
 
CGH was performed as previously described [28] at the Department of Human 
Genetics, Philipps University, Marburg, Germany, by Harald Rieder and Stephanie 
Schneider.  
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 Table 2-7. Sequences of primers used for Pyrosequencing on chromosome 1. 
 SNP Forward Primer Reverse Primer Sequencing Primer 
rs1544124 (ANGPTL1) TGCAGTAATTGACGACAGATG  TCGCCAATTTAAATGACACA CTTGGCACAATTTATTTCTA  
 
 
 
 
rs2280078 (ENSA) CAACTATACTATCAACTTCTCCTGGAA   
  
  
TCATCTTGAGCTTTAGGGATTTT CTTTAACAGCAGAGTAGAGA
rs878471 (MCL1) CGGCTTATGATCAAGAACGA GCTTCAGTCTCGGAACATGAC GACTAAGAATGTAATGGGGA
rs3795572 (PEPP3) TGACACCAAGGACAGCACTT CCCCATCTCTCATCACCTTG TATCCTCGTCAGCCCCAC
 
 
 
 
 
Table 2-8. Sequences of primers used for Pyrosequencing on chromosome 16. 
 SNP Position (bp) Forward Primer Reverse Primer Sequencing Primer 
rs7200919 65874101 CAGAGCAACCAGCGAATACA CAGCCACACTTCAATCTGGA  AAAGTGAAGAGAGCTGCTAT   
 
 
 
 
rs7206718 66007332 
  
  
  
ACAGACCCTCCATGACCAAC ACTCTTTGCCAGGCTCTGTG AGAGGACTCCCAACAGACGT 
rs8057184 66384748 ATCCAGACACTGGCCTTGAG GCATGGTGGCGTATACCTGT TGCTCCAGCCAGTCAAACA
rs12599580 66508114 AGGAGGAAGGCTAGCTGGAG GGGTAGCCTGGAATCCTCTC GAATAATTCCATCCTGTCCT
rs255049 66570972 AGAAACCACATGATGGCACA CCTGGACAGGCTTAGAGACG TTAGTCACCCAGAGGCTGG
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2.2.18 Matrix-CGH 
 
The matrix-CGH experiments have been conducted in collaboration with the Division of 
Molecular Genetics (DKFZ, Heidelberg). Two different kinds of chip were available: a 
chromosome 1 specific chip and a whole genome chip. The chromosome 1 specific chip 
contained DNA from 50 BAC clones mapping on 1q and prepared as described before in 
the department of Human Genetics in Essen. In addition DNA from 215 other clones 
covering the whole genome and prepared in Heidelberg were spotted together on this 
chip. The open air hybridization was made in Essen and the analysis was a share work 
from Essen and Heidelberg.  
The whole genome chip was fully prepared and analysed in Heidelberg, with DNA from 
retinoblastoma coming from Essen, for description of the methods please refer to 
Zielinski et al. (manuscript submitted). 
 
2.2.18.1 Chromosome 1 specific chip 
 
The BAC DNAs prepared in Essen were spotted in Heidelberg.  
Tumour DNA and reference DNA from healthy donors (300 – 500 ng) were differentially 
labelled with Cy3- / Cy5- conjugated dCTP by use of the BioPrime DNA Labeling Kit 
(Invitrogen, Karlsruhe Germany). Unincorporated nucleotides, random primers and dyes 
were removed by the use of MicroCon YM30 Spin Columns (Millipore, Schwalbach 
Germany). Incorporation of dyes into the labelled DNA was determined by UV-
spectrophotometry. 10 µg each of tumour- and reference DNA were combined with 300 
µg human Cot-1-DNA (Roche Diagnostics, Mannheim, Germany) and suspended in 125 
µl UltrahybTM hybridization buffer (Ambion, Bad Soden Germany). Denaturation of 
combined DNAs was performed at 75°C for 10 minutes followed by preannealing at 37°C 
for 30 minutes. The hybridization was performed on a rocking shaker (Shaker S4, Elmi, 
Riga, Latvia) for 48 hours at 37°C. Slides were rinsed with PN Buffer and washed with 
Wash A 15 min at 45°C for 2 times, and then dried by centrifugation at 500 rpm for 1 
minute following by 1500 rpm for 1 minute. 
The data acquisition with scanning was performed in Heidelberg, processing and analysis 
was a common work from both institutes.  
 
 35
Material & Methods   
 
2.2.19 Expression analysis 
 
For microarray analysis nucleic acids to be analyzed must be labelled and hybridized to 
oligonucleotide arrays. These steps were performed in the microarray core facility under 
the supervision of Ludger Klein-Hitpass at the Institut Für Zellbiologie from the 
University of Duiburg-Essen.  
Signal intensities and detection calls for further analysis were determined using GeneChip 
Microarray Suite (MAS) 5.0 Software (Affymetrix). Scaling across all probe sets of a 
given array to an average intensity of 1000 units compensated for variations in the amount 
and quality of cRNA samples and other experimental variables. Further processing of the 
average difference values and gene information was performed in Excel 2000 (Microsoft).  
 
2.2.20 Statistical analysis of genetic findings and clinical manifestation 
 
The Wilcoxon test (normal approximation) was used to test if genes are differentially 
expressed between tumours with or without 1q gain. “Significance Analysis of 
Microarrays” (SAM, Stanford University, CA, USA [51]) was used to identify genes that 
are consistently differentially expressed between classes of tumours – as defined by 
distinct patterns of DNA copy number in 1q32 – regardless of the absolute RNA 
expression level. 
 
Detailed information on clinical presentation, treatment and follow up of patients were 
obtained. We used a data warehouse software (Cognos Series 7.1, Cognos incorporated) 
to link up all clinical and genetic data and to set the stage for data mining, which was 
performed using the tools provided by the software environment. Statistical evaluation of 
the findings was performed using the JMP 5.1 software (SAS Institute) and its cluster 
analysis platform, and InStat 3 for Macintosh. 
 36
Results   
3 RESULTS 
3.1 Identification of target genes on the long arm of chromosome 1 
 
In order to identify retinoblastomas with gains on the long arm of chromosome 1 and to 
narrow down the minimum region with increased copy numbers, two independent 
methods were employed:  
• Matrix-CGH hybridization against cloned DNA from the region of interest 
(custom chips, 3.1.1.1) and Matrix-CGH using arrays of spotted cloned DNA 
representative for the whole genome (3.1.1.2). 
• Quantitative multiplex PCR was used to determine relative copy numbers of genes 
in the candidate region on 1q that was defined by CGH previously (QMPCR, 
3.1.2) 
To confirm the results, we used additional approaches:  
• Genomic Real-Time PCR was employed to determine DNA copy numbers of 
specific genes (3.1.3.1) 
• Pyrosequencing of SNP loci was used to detect allelic imbalances, which often 
accompany an increase in copy number of genomic regions (3.1.3.2) 
• Conventional comparative genomic hybridization (CGH, 3.1.3.3) 
In addition, expression analysis of 21 primary retinoblastomas previously characterised at 
the genomic level on 1q was performed with the Affymetrix microarray chip HG-U133A 
(3.1.4). 
The results obtained by these methods were also used to identify possible associations 
between different patterns of genomic gains on 1q and the clinical manifestation of the 
tumour (3.1.5). 
 
3.1.1 Matrix CGH 
3.1.1.1 Custom chip 
 
Our initial strategy for identification of retinoblastomas with genomic gains in the 
candidate region on 1q was to use matrix CGH with an array of spotted DNA derived 
from BAC clones from this region. The location of the clones used is listed in Table 2-1. 
They cover the minimal region of gain that was previously determined by CGH [28]. 
After preparation, sequence verification, and spotting of BAC DNA we tested the quality 
of matrix CGH with these custom arrays and checked if the results could help to narrow 
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down the candidate region of gains on 1q. First, the quality was checked by hybridization 
with 2 DNA samples with known genomic gains in the region represented by the BAC 
array. The first sample was DNA from a glioma with high level copy number gains of 
material on chromosome 1q, specifically amplification of the MDM4 gene [38, 39]. 
Matrix CGH with our custom chip showed a value of 5.98 for the BAC clone RP11-
430C7, which contains the MDM4 gene. This figure corresponds to a high level 
amplification and is concordant with reported results. Gains were also detected for three 
adjacent clones (Fig 3-1). 
 
Bac clones: 
RP11-430C7 
RP11-284G5 
RP11-74C13 
RP11-90O23 
Fig 3-1. Profile of DNA from a glioma on the custom array-CGH with BACs from 1q. The 
clones are ordered along the abscissa according to their location on the chromosomes with 
clones from telomere of short arm of chromosome 1 on the left and clones from telomere of 
long arm to the right. The clones of the far right are from the Y-chromosome. The threshold 
for gains of material is 1.25. Clones with signals >4 are located on chromosome 1q. 
 
Second, we tested if matrix CGH with the custom chip is suited to detect low level copy 
number gains. For this we used a control DNA from a uveal melanoma cell line (Mel202) 
that has a trisomy 1 and trisomy 6 as determined by cytogenetic analysis (Nareyeck G., 
Zeschnigk M. et al. manuscript under revision). The results of hybridization did not show 
any copy number change on chromosome 1 (Fig 3-2). Possibly, the failure to detect low 
level gains are not due to a problem related to the array but caused by the open air 
hybridization protocol that we used for manual assisted hybridization. This may result in 
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weaker specific signals and higher background noise. It is possible to improve the results 
to some extent by setting new thresholds. To test if useful results could be obtained with 
this adjustment we tested DNAs from 8 retinoblastoma samples that had shown 
chromosome 1q gains in conventional CGH or QMPCR. With matrix CGH gains were 
detected in only 6 of these tumours. The two other tumours with 1q gains were negative in 
matrix CGH. These tumour DNAs showed hybridization signals for 1q-clones that were 
close 1, which corresponds to a normal diploid gene copy number. It was not possible to 
improve these results by setting new thresholds. Thus we concluded that the sensitivity of 
matrix CGH with our custom BAC arrays does not allow to reliably identify the presence 
of gains in the candidate region on 1q in retinoblastomas. 
 Fig 3-2. Profile of the Mel202 cell line on the custom array-CGH with BACs from 1q. The order 
of the clones is the same as in Fig 3-1. 
  
3.1.1.2 Matrix CGH with DNA arrays representing the whole genome 
 
In view of the results obtained with our custom BAC arrays and manual assisted 
hybridization, we decided to perform matrix CGH with a whole genome chip that was 
established by our cooperation partners at the DKFZ Heidelberg in the meantime.  
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Table 3. 1 Imbalanced chromosomal regions detected with whole genome matrix-CGH array. 
 
Tumour No.  
Aberr. 
Imbalanced chromosomal regions detected by matrix-CGH 
M22058 4 enh(1q31.3q44[193.54-246.01], 6p25.3p11.2[0.09-58.73], 
19p13.3q13.42[2.60-63.77])  amp(1p33p33[47.70-48.16]) 
M22590 5 enh(1q21.1q44[141.79-244.84], 2p25.3p12[0.22-81.88], 
11p12p12[37.68-38.64])   dim(10q24.32q26.3[104.18-135.03], 
16q12.1q24.1[47.68-89.64]) 
M22808 10 enh(1q22q22[152.06-152.49], 6p25.3p11.2[0.09-56.69], 
7p22.3p21.3[1.39-8.82],  7p15.3p13 [20.66-44.82], 
7q11.22q36.3[70.46-158.46],19p13.3p13.11[0.21-22.77], 
20p11.23p11.22[20.23-21.54], 20q11.21q13.13[31.22-50.18])  
dim(16p12.1q12.2[49.43-55.39], Xp11.22q23[53.03-113.63]) 
M22860 9 enh(18q11.1q23[17.22-75.94], 19q13.12q13.43[40.17-63.77]) 
dim(1p36.33p36.21[1.06-12.51], 8p23.1p23.1[7.16-8.02], 
12p13.33p11.21[0.64-32.93], 16q12.1q24.3[47.68-89.86], 
17p13.3p11.2[0.38-21.41], 18p11.32p11.31[0.13-6.21], 
22q11.1q13.33[15.62-49.34]) 
M23449 5 enh(1q21.1q32.3[141.79-208.92], 14q21.3q32.2[47.80-96.93], 
17q25.3q25.3[80.82-81.46]) dim(10q23.2q23.32[88.29-92.81], 
21q11.2q21.2[14.63-25.64]) 
M23209 2 enh(2p24.1p24.1[21.20-21.45])  dim(8q24.12q24.12[119.69-119.91]) 
M20517 0  
M22233 4 enh(6p25.3p11.2[0.09-58.73], 19q13.2q13.2[45.08-45.81]), 
dim(13q12.3q14.3[28.81-49.73]) amp(1p34.2p34.2[39.75-40.65]) 
M22641 7 enh(1q21.1q44[142.66-246.01], 2p25.3p12[0.22-80.04], 
6p25.3p12.1[0.09-53.03], 13q32.2q34[96.85-112.83], 
16q21q22.3[64.14-73.26])  dim(6q22.31q22.31[118.62-119.60], 
16q23.1q23.2[78.27-79.88]) 
M22731 5 enh(1q21.1q32.2[142.66-207.74], 5q23.3q31.2[131.41-137.69], 
6p24.3p12.3[8.60-46.97], 14q22.3q22.3[54.57-55.54])  
dim(16q21q22.1[63.16-65.15]) 
M22067 0  
M23215 19 enh(1q21.1q44[141.79-246.01], 2q37.1q37.3[233.54-242.82], 
5p15.32p15.31[5.50-7.53], 5p13.2p13.2[37.00-38.32], 
5q11.2q11.2[55.53-56.29],5q13.2q13.2[72.73-72.97], 
5q23.1q35.3[118.32-180.80], 6p21.33p21.1[31.64-44.29], 
10q24.31q25.1[101.89-105.89], 10q25.2q25.2[111.49-112.17], 
10q25.3q25.3[115.64-115.82], 10q26.11q26.12[119.94-121.60], 
10q26.13q26.3[124.34-134.69], 13q12.13q34[24.65-113.00], 
20p13p13[0.18-3.84], 22q13.2q13.2[40.42-40.72]) 
dim(6q22.33q27[128.38-170.74], 8p23.3p12[4.77-31.06], 
17p13.2p11.2[4.07-18.37]) 
M23869 6 enh(1q21.1q23.3[144.11-158.62], 1q31.3q42.2[194.68-229.94], 
2p25.3p11.2[0.22-89.89], 6p25.3p11.2[0.09-58.73], 
15q21.3q24.1[56.57-72.33])  dim(13q14.2q14.3[46.86-49.87]) 
M24430 2 enh(1q21.1q25.2[141.79-174.53]) dim(9q34.3q34.3[134.42-134.80]) 
M24733 7 enh(1q21.2q44[147.66-246.01], 6p25.3p12.1[0.09-56.84], 
19q13.42q13.42[59.04-59.40]) dim(1p36.33p35.3[1.14-27.85], 
8q22.3q24.3[105.89-146.86], 16p13.2p11.2[2.19-31.07], 
16q12.1q24.3[47.68-89.59]) 
M24794 5 enh(1q21.1q44[141.79-246.01], 2p25.3p14[0.22-64.80], 
6p25.3p21.2[0.09-37.02]) dim(16q24.1q24.1[85.70-86.52], 
17p13.2p11.2[5.60-6.66]) 
M24820 4 enh(1q22.2q44[152.06-165.82],1q25.3q25.3[178.43-180.01], 
1q31.3-q44[195.63-246.01], 6p25.3p11.2[0.09-57.36]) 
 
enh: gain of chromosomal material; dim: loss of chromosomal material; amp: amplification. 
Megabase positions are given in square brackets. Most frequently detected aberrations are 
indicated in bold face. 
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This array is composed of BAC clones that are separated by about 1Mb and cover the 
whole genome. The cooperation partner performed matrix CGH with DNAs from 17 
retinoblastomas using automated hybridization. These tumours were selected from 
specimens that had also yielded RNA suited for expression analysis (see 3.1.4). The 
results of whole genome matrix CGH on these tumours showed all recurrent aberrations 
that are frequently observed by conventional CGH: gains on 1q and 6p, and losses on 16q. 
In addition, a previously unreported high-level amplification was identified in a small 
region on the short arm of chromosome 1 (see insert from Fig 3.10). However, this novel 
aberration is likely to be rare because it was observed in only 1/17 retinoblastoma samples 
(Table 3-1). 
 
3.1.2 Quantitative multiplex PCR (QMPCR) 
3.1.2.1 Establishing and validating QMPCR 
 
As a result of the Human Genome Project, almost complete sequence data have become 
available from most chromosome regions. This has opened the possibility to use QMPCR 
to determine the presence and extent of genomic gains in the candidate region in 
retinoblastoma. In addition to the 1q32 region, which was identified by CGH, we 
established QMPCR for the detection of copy number changes in another chromosome 1 
region, 1q21. This second region was included because evaluation of RNA expression 
analysis with SAM (see Table 3.2) suggested that this region might show gains in some 
retinoblastomas. We have chosen 30 PCR targets from 1q21 and 1q32 (table 2-1). 
Individual PCR targets were co-amplified in 5 multiplex sets. In addition, each multiplex 
reaction contained primers for amplification of two control targets outside of chromosome 
1. These controls were used for normalization of the intensities of product signals within 
individual multiplex reactions. To validate QMPCR, we performed several control 
experiments on samples with known copy numbers. In addition, we analyzed DNA from 
two tumours representing different stages of glioma. It has been reported that these two 
specimens have amplifications on 1q32, a finding that had been confirmed by Southern 
Blot hybridization [38, 39]. With QMPCR on DNA from these tumours we detected high 
level gains of the loci MDM4, GAC1, PIK3C2B and PEPP3. These results are in 
agreement with the findings reported previously [38, 39] (Fig 3-3). To determine if 
QMPCR can detect low level gains we also analyzed the uveal melanoma cell line Mel 
202 with trisomy 1 and trisomy 6. QMPCR results showed values corresponding to 3 
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copies for all loci on chromosome 1 and for the control locus on chromosome 6q (median 
= 1.50, quartiles [1.44;1.55], Fig 3-3). This indicates that QMPCR can reliably 
discriminate between DNAs that have two or three copies of the regions targeted by PCR. 
 
3.1.2.2 QMPCR of DNA from specimens of primary retinoblastoma 
 
QMPCR was performed on DNA from samples of primary retinoblastoma from 76 
patients. Most of these patients (n=73, 96%) were diagnosed with isolated unilateral 
retinoblastoma. The three remaining patients had isolated bilateral retinoblastoma. The 
results of QMPCR, which are shown as a cell plot in Fig 3-4A, showed a complex pattern 
of gains. Using a threshold for discrimination (definition of the threshold see section 
2.2.12) we found that gains on 1q21 or 1q32 are present in 34 of 76 (45%) samples. None 
of the retinoblastomas showed amplification at high levels comparable to the findings in 
the glioma samples that were analyzed as controls (3.1.2.1). The tumour with the highest 
gains on 1q had a median copy number of 4 (2.03 [1.92; 2.41]). The pattern of gains did 
not simply point out a minimum region of gains on 1q21 or 1q32. However, a closer 
analysis showed recurrent patterns. Among the tumours with gains of material on 1q, four 
tumours had no gain at one border of the 2 regions investigated: G319 had no gain of the 
loci ZNF281 and ELF3 from 1q32, the tumour M74 had gain of material of all but the 2 
telomeric loci (COG2 and SMYD3), M23449 had higher copy number on 1q21 while the 
loci on 1q44 (COG2 and SMYD3) were normal, and M10288 had no gain at the first locus 
on 1q21 (GJA5). These observations allow to define more precisely the regions of gains 
on 1q in retinoblastoma.  
 
3.1.2.3 QMPCR of DNA from retinoblastoma cell lines 
 
We also performed QMPCR on DNA from retinoblastoma cell lines WERI-Rb1, Y-79, 
RBL 30, RB247C3, RB383, and RB355. All 6 cell lines showed genomic gains at all 1q 
loci analyzed here (Fig. 3-5). On the whole, levels of gains in cell lines were higher 
compared to primary retinoblastoma. Gains were most pronounced in DNA from the cell 
line WERI-Rb1 (2.98 [2.62; 3.24]). In RB355 and RB383 the levels of gains for loci 
within 1q21 were distinct from those of loci in 1q32: values of 1.52 [1.48; 1.51] on 1q21 
and 2.14 [2.07; 2.26] on 1q32 for RB355, and 2.45 [2.38; 2.82] on 1q21 and 1.58 [1.52; 
1.70] on 1q32 for RB383.  
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1q21           1q32       1q44 
 
Fig 3-3 Validation of QMPCR. QMPCR was used to determine relative copy numbers of loci on 
chromosome 1q in DNA from the cell line Mel202 (scale on left axis, data points in green) and 
in DNA from two gliomas (scale on the right axis, blue and pink). 
We had the opportunity to compare results of QMPCR obtained in DNA from a cell line 
(RBL 30) with those of the primary tumour (G319) that had been used to establish this 
cell line. Comparison of DNA gains on 1q showed that the genome of the cell line has 
obviously faithfully conserved the profile of gains that is detected in the primary tumour 
(Fig. 3-5 A). It is to be noted that the close correspondence of the two profiles also 
indicates that the error due to measurement is rather low. In fact, such a close correlation 
of results strongly suggests that QMPCR permits reliable relative quantification of low 
levels of copy number gains. 
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1q21         1q32 
A                B 
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(page 44) Fig. 3-4. A, Cell plot of gene dosage from 74 primary tumours (2 tumours are not 
included because of missing data for some target genes) color scale: blue corresponds to a 
QMPCR result of 1 (2 copies); dark red corresponds to a result of 3 (6 copies). B, hierarchical 
cluster Ward‘s method, classes ng (dark blue), ig (light blue-pink), hg (red-pink), and chg 
(dark red). 
 
 
ig 3-5. Copy number in cell lines and a primary tumour determined by QMPCR. A, gene copy 
 
F
number of cell line RBL30 (data points in blue), primary tumour G319 (green) and cell line 
WERI (black). B, Cell plot of gene dosage from several cell lines. 1   2    3    4    5  
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3.1.3 Confirming the results of QMPCR by independent methods 
3.1.3.1 Genomic Real-Time PCR 
 
The basic principle of Real-Time PCR is to monitor the amount of specific product that is 
synthesized during the progress of the reaction. We used the TaqMan detection 
technology, which provides high specificity and sensitivity and, in principle, allows 
detection of loss or gain of a single copy of a gene. We used this method to check gene 
copy number results obtained by QMPCR (3.1.2). We analyzed targets specific for the 
GAC1, REN, and MDM4 genes in 65 retinoblastomas. To compare the results, we 
determined the correlation coefficients of data obtained for the same gene. The correlation 
coefficients (Pearson’s correlation coefficient: R) of QMPCR data and results obtained by 
Real-Time PCR were 0.54, 0.40, and 0.51 for GAC1, REN and MDM4, respectively. A 
graphical representation of correlation data for the GAC1 gene is shown (Fig3-6). 
 
 
Fig 3-6. Regression analysis of Real Time PCR and QMPCR data obtained 
for the GAC1 gene (dotted lines: curves of 95% confidence limits). 
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3.1.3.2 Pyrosequencing of SNP loci 
 
At a heterozygous polymorphic locus, the relative copy numbers of the two alleles are 
expected to be equal (1:1) in normal constitutional DNA. If this locus is part of a region 
that has undergone copy number changes in a tumour, the allele signal ratio will depart 
from unity – i.e. will show allelic imbalance – if copy number changes affect only one of 
the two allelic regions (which is most often the case). With pyrosequencing it is possible 
to obtain a precise relative quantification of SNP alleles [49, 50]. In order to detect allelic 
imbalance in tumour DNA, it is necessary to perform two rounds of pyrosequencing 
analyses for each SNP and each patient. Analysis is performed on constitutional DNA 
(peripheral blood) first to test if a patient is heterozygous at a given SNP locus. This result 
is also used to normalize the signal ratio obtained in the corresponding tumour. Second, 
SNPs of heterozygous individuals are analyzed in tumour DNA. We found little variation 
of ratios in normal constitutional DNA: average ratios [(allele1/allele2) exp1/ 
(allele1/allele2) exp2] were 1.006, 1.051, 0.961 and 0.971 for SNPs in ANGPLT1, ENSA, 
PEPP3 and MCL1genes, respectively (variation between two experiments, exp1 and 
exp2). This suggests that the stochastic measurement error is low. 
 
 
Fig 3-7. Regression analysis of pyrosequencing and QMPCR data obtained 
for the ENSA gene (dotted lines: curves of 95% confidence limits). 
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When comparing the results of pyrosequencing of SNP loci with those of QMPCR it must 
be kept in mind that pyrosequencing determines allelic imbalance, i.e. a ratio of two 
alleles at one locus. However, with QMPCR the copy number of a locus is determined 
relative to another locus. To compare the results we determined the correlation 
coefficients of results obtained for three loci within the 1q21 and 1q32 (ENSA, PEPP3, 
and MCL1). The correlation coefficients (Pearson’s correlation coefficient: R) of QMPCR 
data and results obtained by pyrosequencing were 0.47, 0.24, and 0.54 for ENSA, PEPP3 
and MCL1, respectively (Fig 3-7). 
 
We also tested a fourth locus that is mapped to the intermediary region (ANGPTL1). 
Although this precludes to correlate allelic imbalance at ANGPTL1 gene with individual 
QMPCR results, the findings at this locus fit in the general pattern: of 18 tumours 
heterozygous for this SNP, 5 showed allelic imbalance, and these 5 tumours had also 
allelic imbalances on both 1q21 and 1q32.  
 
3.1.3.3 Conventional comparative genomic hybridization (CGH) 
 
From 68 of the 76 primary tumours investigated by QMPCR (3.1.2.2), we also had CGH 
results (CGH was performed at the Department of Human Genetics in Marburg). CGH 
data were compared with QMPCR and, in addition, to check the validity of the control 
used for normalisation in QMPCR and located on chromosome 10. Comparing these 
datasets we found that all 18 (26%) samples with 1q gains in CGH also showed gains in 
QMPCR. Of 50 (74%) samples without 1q gains in CGH, 37 (54%) also showed normal 
copy numbers of 1q loci in QMPCR. In 13 samples (19%) without CGH alterations on 1q, 
gains were detected by QMPCR. It has to be noted that in 7 of these tumours, copy 
number gains determined by QMPCR were relatively low and present at only some of the 
loci tested. Possibly, gains in these samples are missed by CGH because the resolution of 
this technique, both spatial and quantitative, is inferior to that of QMPCR [31, 52]. 
The pattern of 2 regions of gain on 1q obtained previously in QMPCR with the primary 
tumours and the cell lines was confirmed in CGH. The RBL30 cell line (derived from the 
G319 tumour) showed 2 distinct regions of gain. These 2 regions are also highlighted by 
the results from cell line WERI-Rb1 showing 2 distinct peaks of gains centred on 1q21 
and 1q32 (Fig. 3-8). 
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Fig 3-8. Fluorescence ratio CGH profiles of chromosome 1 showing distinct peaks of gains at 
1q21q22 and 1q32 in (a) WERI-Rb1 and (b) RBL30. An increased dosage of entire 1q was 
found in (c) Y-79. 
 
3.1.4 Expression data 
 
RNA for expression analysis was available from 21 primary retinoblastomas. Of these, 
nine tumours had genomic gains at all loci in the 1q32 region. Ten tumours showed no 
gains in QMPCR. The pattern of gain on 1q32 in the remaining two tumours was 
intermediary with some loci showing gains while other loci had normal copy number. 
Significance Analysis of Microarray (SAM) was used to identify genes that, regardless of 
the absolute RNA expression level, are consistently differentially expressed between the 9 
tumours with gains of all loci in the 1q32 region and the 10 samples without gains. A list 
of the first 150 genes differentially expressed is provided in Table A in annexe. 
With respect to the chromosomal localization of the genes identified by SAM it is to be 
noted that the top 45 of these genes (Table 3-2) includes 22 genes that are located on the 
long arm of chromosome 1. We also noticed that 10 of these 22 genes are located in 1q21. 
This prompted us to establish additional QMPCR assays for the detection of DNA copy 
number gains of loci in the 1q21 region (Table 2-3). 
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Table 3-2. Genes overexpressed in tumours with gains on 1q (from SAM) 
 
Gene Name Affy. # Location 
Fold 
Change 
q-value  
(%) 
 P 
ZNF281 218401_s_at Chr:1q32.1 1.51 4.90 0.0003 
SYT11 209197_at Chr:1q21.2 1.43 4.90 0.0004 
ENSA 221486_at Chr:1q21.2 1.62 4.90 0.0004 
SYT11 209198_s_at Chr:1q21.2 1.69 4.90 0.0003 
ADAR 201786_s_at Chr:1q21.1-q21.2 1.33 4.90 0.0005 
SH3GLB1 210101_x_at Chr:1p22 1.41 4.90  
MCL1 200797_s_at Chr:1q21 1.38 4.90 0.0029 
SH3GLB1 209091_s_at Chr:1p22 1.48 4.90  
RNF19 220483_s_at Chr:8q22 1.38 4.90  
HTCD37 209586_s_at Chr:1q21 1.70 4.90 0.0005 
KIAA0992 200897_s_at Chr:4q32.3 1.66 4.90  
SNX27 221498_at Chr:1q21.2 1.48 5.52 0.0022 
LASS2 222212_s_at Chr:1q21.2 1.63 5.52 0.0022 
FLJ12806 220199_s_at Chr:1q42.12 2.44 5.52 0.0017 
M11S1 200723_s_at Chr:11p13 1.38 5.52  
DUSP12 218576_s_at Chr:1q21-q22 1.42 5.52 0.0017 
POGK 218229_s_at Chr:1q23.2 1.46 5.52 0.0003 
CA12 204508_s_at Chr:15q21.3 3.99 5.52  
CDC42BPA 214464_at Chr:1q42.11 1.55 5.52 0.0022 
SLC37A1 218928_s_at Chr:21q22.3 2.63 5.52  
WDR26 218107_at Chr:1q42.12 1.40 5.52 0.0017 
JTB 210927_x_at Chr:1q21 1.48 6.38 0.0013 
SSA2 210438_x_at Chr:1q31 1.48 6.59 0.0013 
ARPC5 211963_s_at Chr:1q25.1 1.53 6.59 0.0009 
RPS6KB1 211578_s_at Chr:17q23.2 1.54 8.30  
JTB 210434_x_at Chr:1q21 1.55 8.30 0.0017 
C1orf37 212165_at Chr:1q31.3 1.63 8.30 0.0029 
MAPKAPK5 212871_at Chr:12q24.13 1.36 8.30  
NFYA 215720_s_at Chr:6p21.3 4.11 8.30  
RBMS1 203748_x_at Chr:2q24.2 2.74 8.30  
DKFZP434B168 222250_s_at Chr:1p36.13-q42.3 1.45 8.30  
Ufc1 217797_at Chr:1q23.1 1.50 8.30 0.0025 
CENPF 207828_s_at Chr:1q32-q41 2.14 8.30 0.0022 
PSME4 212219_at Chr:2p16.1 1.78 8.30  
PPP2R2A 202313_at Chr:8p21.1 1.60 8.30  
SLC25A3 200030_s_at Chr:12q23 1.27 8.30  
RBMS1 207266_x_at Chr:2q24.2 3.19 8.48  
CGI-01 212405_s_at Chr:1q24-q25.3 1.54 9.94 0.0022 
KAB 212746_s_at Chr:1q44 1.72 10.17 0.0037 
GPSM2 205240_at Chr:1p13.2 1.76 10.17  
SEMA4C 46665_at Chr:2q11.1 1.63 10.17  
EIF5B 201027_s_at Chr:2p11.1-q11.1 1.54 10.17  
ARID4B 221230_s_at Chr:1q42.1-q43 1.47 10.17 0.0033 
GPR161 214104_at --- 2.98 10.17  
VARS2 201796_s_at Chr:6p21.3 2.32 10.17  
 
 
 
 P value from Wilcoxon test, normal approximation, genes located on 1q are 
typed in bold face. 50
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We also evaluated the expression of the loci that were targeted by our QMPCR assay. Of 
these 30 genes, RASSF5 was not represented as on the Affymetrix U133A chip. Eight 
genes were not expressed at all in our retinoblastoma samples: GJA5, ELF3, MYOG, 
SOX13, REN, PEPP3, IKBKE and CNTN2. PIK3C2B and GAC1 were present in only 11 
and 6 tumours, respectively. Of these genes, only PIK3C2B was found to be present in 
normal retina.  
 
Table 3-3. Expression of genes investigated by QMPCR 
Locus Gene Symbol Median expression 
in tumours: Without 
gain/ With gain 
Expression 
in Normal 
retina 
 
1q21 GJA5 A  A 
 MCL1 6562.1/  9268.3** 838.6 
 ENSA 3593.35/  6064.2** 3229.8 
 LASS2 1133.1/  1892.8** 2184.4 
 HTCD37 1508.3/  2372.3** 1928.7 
 SNX27 1066.3/  1600.6** 819.1 
 JTB 7327.95/  11227.2** 5743.1 
 ADAR 3967.65/  5178.3** 5333.7 
 SYT11 2936.75/  4511.2** 1916.8 
1q32 ZNF281 1612.6/  2300.3** 838.6 
 ELF3 A  A 
 MYOG A  A 
 FMOD 540.2/  610.3 2667.4 
 LAX 336.6/  323.2 308.1 
 SNRPE 6935.75/  9340 5188.7 
 SOX13 A  A 
 REN A  A 
 PEPP3 A  A 
 PIK3C2B 722.15/  720.5 889.9 
 MDM4 365.75/  355.7 213.4 
 LRRN5 (GAC1) 399/  512.9 A 
 CNTN2 A  A 
 RBBP5 588.65/  580.9 423.6 
 HUCEP11 1942.65/  2227.6 1233.5 
 RAB7L1 375.95/  286.8 951.6 
 IKBKE A  A 
 RASSF5 n.r.  n.r. 
1q32-41 CENPF 4503.7/  7661.8** A 
1q42 COG2 1401.1/  1541.2 1292.4 
1q44 SMYD3 1112.25/  1339.7* 673.5 
 
Median of expression values from tumours without or with gain of 
material on 1q, and expression value in normal adult retina. (* 
P<0.05; ** P<0.0005; Wilcoxon test normal approximation; A: 
Absent, gene not expressed; n.r.: not represented on the array). 
 
 
 
The 20 other genes were called present in at least 18 of the 21 tumours (Table 3-3). Of 
these 20 genes, 11 showed differential expression between tumours with gains and 
without gains thus reflecting the effect of increased gene dosage. Even though the fold 
changes are rather low (Table 3-2), they indicate that the two groups of tumours have a 
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different expression pattern. Most of the genes differentially expressed belong to the 1q21 
region; only two genes, ZNF281 and CENPF, belonging to 1q32 were differentially 
expressed.  
When analyzing the expression pattern of genes in 1q21 and 1q32, we found the same 
genes expressed in normal adult retina and in primary retinoblastoma. It has to be noted 
that 5 genes were much higher expressed in the primary tumours than in the normal adult 
retina. Among these genes SMYD3, ZNF281 and MCL1 were present in the normal retina 
but at inferior levels compared to both groups of tumours (with and without gains on 1q), 
and CENPF was absent in normal adult retina. JTB was also expressed at higher levels in 
tumours than in retina, but the level of expression in retina was almost the same than the 
one in the tumours without gains on 1q. One gene only, FMOD, was expressed at lower 
level in the tumours compared to retina. 
 
3.1.5 Genomic gains in 1q and clinical manifestation 
 
In order to determine groups of tumours defined by distinct patterns of gains on 1q the 
multivariate DNA copy number data was analyzed by unsupervised classification 
algorithms. We have chosen this approach because the threshold method that was used to 
determine the minimum region of gains on 1q does not take into account the multivariate 
nature of the results. We applied different algorithms for agglomerative hierarchical 
clustering (single linkage, complete linkage, average linkage, centroid linkage, and 
Ward’s method) to classify the copy number patterns on 1q. All these methods identified 
essentially the same 4 classes of tumours (Fig. 3-4B). One class comprises 7 tumours 
(9%) with increased copy number for all the 30 genes on 1q and copy numbers ranging 
from 3 to 6 (QMPCR values: 1.97 [1.78; 2.19]). This class is later referred to as chg 
(complete and high gain).  Another class distinguished by the cluster algorithms 
comprises 12 tumours (16%). All tumours in this class show gains at most loci with copy 
numbers ranging up to 5 (QMPCR values: 1.64 [1.53; 1.77]). This class is later referred to 
as hg (high gain). The largest class contains 35 (47%) samples with no gains (abbreviated 
ng, QMPCR values: 1.11 [1.04; 1.18]). The remaining 20 (27%) samples represent a 
fourth class of tumours showing intermediate levels of DNA gains (abbreviated ig, 
QMPCR values: 1.35 [1.25; 1.45]). 
We tested for associations between the assignment of a tumour to one of the four classes 
of 1q gains and various aspects of clinical manifestation. Knowing that several aspects of 
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clinical manifestation are different between patients with bilateral and isolated unilateral 
retinoblastoma, we only analyzed data from the latter group of patients. Also, in 
Germany, almost all patients with isolated unilateral retinoblastoma undergo enucleation 
as primary therapy. Therefore, our findings are likely to be representative for this group as 
only very few patients are not included in our study. 
We observed a strong association with age at diagnosis (Fig. 3-9): most patients with 
tumours with no 1q gains (ng) were young (26/31 patients, range 0 to 18 months of age), 
whereas patients whose tumours showed gains (chg and hg) were older at time of 
diagnosis (17/17 patients, range 10 months until 5 years of age). The distribution of age at 
diagnosis of patients with tumours in intermediate gains class (ig) is in between that of ng 
and chg/hg tumours. The difference of the distributions of age at diagnosis in patients 
with chg/hg tumours and either ng or ig tumours is statistically significant as is the 
difference between that of patients with ng and ig tumours.  
 
 
 
Fig 3-9. Cumulative proportion of patients diagnosed for Rb by age at diagnosis (in months) 
grouped by the pattern of genomic gains in chromosome 1q. Distribution of age at diagnosis is 
significantly different between classes chg and ng (P=0.0032) and between classes hg and ng 
(P=0.0003). 
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Although vitreous seeding was more frequent in patients with chg and hg tumours (Table 
3-4), vitreous seeding was also observed in almost half of the patients with ng tumours. 
The histology of most ng tumours was completely differentiated whereas chg and hg 
tumours frequently showed only partial differentiation or were undifferentiated. The only 
2 tumours with fully undifferentiated histology were genetically classified as chg.  
We observed no significant differences between classes with 1q gains and other aspects of 
the tumour behaviour or genetic status of the RB1 gene including tumour size, tumour 
calcification, tumour necroses, the type of mutation on the RB1 gene or allele loss at this 
locus. 
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 Table 3-4. Association of clinical characteristics and gene dosage, according to 
the class of the tumours (number of tumours).     chg hg ig ng 
Tumor size 25 - 50 % 4 4 10 21 
  >50% 0 3 2 1 
Differentiation Undifferentiated 1 1 2 0 
 Partially differentiated 4 6 11 13 
  Completely differentiated 0 2 5 18 
Vitreous No seeding 0 0 5 9 
seeding Local seeding 1 1 2 5 
 Diffuse seeding 5 5 6 6 
Necrosis Necroses 6 8 14 27 
  No necrosis 0 1 1 1 
Calcification Calcification 5 8 15 24 
  No calcification 0 0 0 1 
None of the tumour characteristics is significantly associated with gene dosage 
changes in 1q. chg, complete high gain, hg, high gain, ig, intermediate gain, ng, 
no gain. 
2 Identification of an oncogene on chromosome 1p 
2.1 Matrix-CGH 
atrix-CGH with a genome chip that contains BACs that represent all chromosomes was 
rformed at the DKFZ in Heidelberg. These analyses resulted in the identification of a 
vel high-level amplification on 1p34.2 in one of 17 retinoblastoma specimens tested 
22234). In this tumour, 4 BACs clones showed copy number gains (name and location 
e shown in the insert of Fig 3-10, values ranging from 5.3 to 7.9). These BACs contain 
known genes: TRIT1, MYCL1, CAP1, PPT1, RLF, ZMPSTE24, COL9A2, RIMS3, and 
YC (NCBI build 35.1).  
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3.2.2 RNA expression analysis 
 
RNA expression data (2.2.19) were available from all 17 tumours that were analyzed by 
whole genome matrix CGH. All 9 genes known to be contained on the BACs with gains 
were represented by probe sets on the Affymetrix chip. One gene, CAP1, was represented 
by 2 probe sets. All but one (NFYC) of these genes had markedly higher expression levels 
in the tumour with the 1p34 gain compared to the tumours without genomic gains in this 
region (Fig 3-10). As genes located adjacent to BACs with amplification, e.g. PPIE and 
NFYC, showed no higher expression the region with overexpressed was restricted to the 
genes contained on the positive BAC clones. Although 16 tumours showed no genomic 
gains in 1p34 region represented by these BACs, there was some variation of expression 
of the genes in this region: e.g. COL9A2 showed higher expression in tumours M22069 
and M23819, RIMS3 and MYCL1 were overexpressed in M22069 and M22734, 
respectively. However, it is to be noted that expression of these genes did not reach the 
levels observed in tumour M22234 with DNA gains in this region. 
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3.3 Identification of allelic loss on chromosome 16 
 
Regions that acquire loss of genetic material during tumorigenesis can harbour tumour 
suppressor genes. In retinoblastoma, markers on the long arm of chromosome 13 
frequently show LOH because this region contains the RB1 tumour suppressor gene. In 
addition, CGH analyses have identified loss of genetic material on the long arm of 
chromosome 16 (16q) in 18 to 46% of retinoblastomas. The region on 16q that is 
commonly lost may harbour a tumour suppressor locus with the retained allele inactivated 
by a local mutation or silencing by hypermethylation of the promoter. We have employed 
different methods to narrow down the location of this potential tumour suppressor gene: 
• Microsatellite analysis (MSA) was used to determine allele loss (3.3.1). This study 
comprised 10 polymorphic microsatellite loci located on 16p and 16q22, a region 
previously highlighted by the results of Marchong et al. [40]. 
• Genotyping by pyrosequencing was used to confirm the results obtained with MSA 
(3.3.2) 
• A methylation specific PCR assay was used to detect hypermethylation of the 
promoter of the CDH11, the candidate tumour suppressor gene on 16q22 proposed by 
Marchong et al. (3.3.3) 
Furthermore, we analyzed the expression of the genes that are located in the region on 
16q investigated by microsatellite analysis (3.3.4), and tested if parameters of clinical 
manifestation are correlated with the allele loss status of chromosome 16 (3.3.5). 
 
3.3.1 Microsatellite analysis (MSA)  
 
Allele loss by microsatellite analysis (MSA) was determined in those 21 tumour samples 
that were also analyzed on the RNA expression level. Examples of loci with LOH and 
retention of heterozygosity are shown in Fig 3-11. In 3 of the 21 tumours investigated, all 
the informative markers on 16q showed allele loss (Fig 3-12). Interestingly, one tumour 
(M24794) had loss of only one of the informative markers tested on 16q. It has to be 
noted that the two markers flanking this locus were informative and had no loss of 
heterozygosity. No tumour showed allele loss of a marker on the short arm of 
chromosome 16. 
CGH data were available from 16 of the tumours tested by MSA. Results were concordant 
in 15 of the cases. One tumour (M23818) had a loss of material of the whole long arm of 
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chromosome 16 in CGH that was not detected in MSA: two of the eight loci investigated 
by MSA on 16q were informative and showed retention of both alleles in tumour DNA. 
This discrepancy between MSA and CGH result could be due to a homozygous deletion 
because in this case the CGH would detect a loss that MSA misses (the tumour tissue 
contains a little quantity of normal tissue that is the target of PCR in the MSA). However, 
our results are not conform with this possibility because the MSA which was performed 
in a multiplex PCR assay showed that the peak areas of the two heterozygous loci were 
comparable to those of homozygous loci. These results allow us to conclude that our 
MSA results are valid. 
Results from matrix-CGH were available from 16 tumours tested for 16q allele loss. The 
status of chromosome 16 was concordant for 13 tumours. Two tumours showed losses of 
material in matrix-CGH that were not detected in MSA. The tumour M24794 with loss of 
only one marker in MSA also showed loss of a narrow region in matrix-CGH. This loss 
was confined to three BAC clones on 16q24. The clones were not located in the same area 
than the STR marker, and losses of these clones could not be detected in MSA as the 
region was not covered. The losses detected in this tumour with these methods were very 
confined, and thus we decided to use genotyping of SNPs by PSQ to delimitate the extent 
of allele loss in the region neighbouring the marker D16S3085.  
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3.3.2 PSQ 
 
The STR D16S3085 that was the only marker with LOH in tumour M24794 is located at 
66,225,096 bp on chromosome 16 (NCBI build 35.1). For further LOH analysis we have 
chosen five SNP loci with known allele frequencies in the regions flanking this location 
(Table 2-8). We have investigated 20 tumours and found that 42% of the loci were 
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heterozygous. Allele loss was observed only in the 3 tumours that had shown LOH in 
MSA (Fig 3-13). The tumour M24794 did not show LOH at any of the SNPs analysed. 
Unfortunately, the centromeric SNPs rs7200919 and rs7206718 were not informative (i.e. 
homozygous in constitutional DNA) thus precluding to further delineate the region 
showing with LOH. Based on these data, the minimum region of LOH in tumour M24794 
has an extent of 1,270 kbp.  
 
3.3.3 MSPCR 
 
Aberrant methylation of gene promoter regions is a frequent genetic alteration that can be 
associated with tumorigenesis as it can cause transcriptional silencing and, consequently, 
loss of gene function. In a recent report from Marchong et al. it was proposed that the 
CDH11 gene is the target of allele loss on chromosome 16 in retinoblastoma. This 
prompted us to set up an assay to detect hypermethylation of the promoter of this gene. 
We have investigated 54 tumours for CDH11 methylation (Fig 3-14). In addition to 
tumours samples that were obtained from the Augenklinik in Essen, we also analysed 
samples sent to us from an outside laboratory (Zerrin Onadim, Retinoblastoma Genetic 
Screening Unit London NHS Trust, UK). We have also investigated the four tumours 
showing LOH in MSA. In three of these tumours the LOH region included CDH11. In 
tumour M24794 the region with LOH did not include the CDH11 locus (Fig 3-15). 
The result of the PCR with the primer pair specific for methylated DNA on the positive 
control sample (bisulfite modified fully methylated DNA) showed the expected specific 
product. No fragment was amplified from the positive control when using primers specific 
for unmethylated DNA.  
PCR with primer pairs specific for unmethylated DNA amplified a product of expected 
length in each of the 54 and 4 tumours investigated. However, no PCR product was 
obtained with methylated specific primer pairs thus indicating that no promoter 
methylation of CDH11 is present in any of the tumours investigated.  
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(page 62) Fig 3-14. Gel electrophoresis of products of MSPCR on 54 tumours after bisulfite 
treatment.  
Gel electrophoresis with pUc marker (M), each tumour is represented by 2 slots: 1st slot is the 
PCR product obtained with methylated specific primers (m), 2nd slot is the PCR product 
obtained with unmethylated specific primers (u). Red stars: positive control (PC) for the 
methylated specific primers with artificially methylated DNA treated with bisulfite. 
 
 
 
 
 
Fig 3-15. Gel electrophoresis of products of MSPCR on the 4 tumours 
showing LOH in MSA: M19484 (M1), M22590 (M2), M22860 (M3), 
M24794 (M4). Legend as in Fig 3-14, Negative Control (NC) 
 
3.3.4 Expression data 
 
For expression analysis of the genes on chromosome 16 data of the Affymetrix chip 
hybridization were used (U133A). On this array, CDH11 is represented with 2 probe sets. 
One of the probe sets, 207172_s_at, was expressed in 9 of the tumours investigated with 
MSA and PSQ. The other probe set, 207173_x_at, was present in all the tumours (Fig 3-
16). CDH11 was also expressed in normal retina (both probe sets). Another potential 
target gene, CDH1, is also represented by two probe sets. One of them, 201130_s_at, 
showed absent expression in all tumours investigated. The other probe set showed 
expression in one tumour only. Both CDH1 probe sets showed that this gene is expressed 
in normal adult retina. Another gene of the cadherin gene cluster, CDH5, was present in 1 
tumour and in adult retina.  
Analysis of genotyping and expression data did not reveal a correlation between tumours 
with LOH and loss or reduction of expression of genes on 16q. 
 
3.3.5 Association with clinical parameters 
 
We have tested the tumours for association between clinical parameters and their status on 
16q. From these 21 tumours, 3 were from patient with bilateral retinoblastoma and 3 other 
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were from patient with unilateral retinoblastoma but with a mutation in constitutional 
DNA (inherited). The other patients had all unilateral not inherited Rb.  
No correlation could be found between the status on 16q and the age at diagnosis, the type 
of retinoblastoma (uni-bilateral, inherited or sporadic). 
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4 DISCUSSION 
 
Mutations affecting both alleles of the RB1 gene are required to initiate retinoblastoma. 
Nevertheless, other genetic alterations are necessary for progression to a malignant 
tumour. Cytogenetic and CGH analyses, which both can identify alterations on a genomic 
perspective, have shown recurrent aberrations in retinoblastomas. Although these changes 
often affect large parts of chromosomes, the functional target of these alterations may be 
as small as a single gene. As the resolution needed to identify these genes is below the 
level of conventional cytogenetic and CGH methods we have used different techniques to 
determine the specific targets of mutations that occur during progression of 
retinoblastoma. 
 
4.1 Gains on the long arm of chromosome 1 
4.1.1 Frequency and location of DNA gains on 1q 
 
With QMPCR 34 of 76 (45%) retinoblastomas were found to have gains involving 1q21 
or 1q32. This proportion compares well to reported studies based on CGH, which have 
shown gains of material on chromosome 1q in 40 to 50% of retinoblastomas [25-28]. 
While the QMPCR assays showed relatively clear patterns of copy number changes, 
interpretation of the data obtained with pyrosequencing and Real Time PCR, which were 
used as alternative methods to confirm the presence of 1q gains, was not straightforward. 
The results of pyrosequencing on DNA from peripheral blood DNA showed very little 
variance. This is a prerequisite when determining allelic imbalances by relative 
quantification of allele signals in tumour DNA. However, we found that in a few tumours 
the pattern of allelic imbalances detected by pyrosequencing was distinct from that of 
DNA gains identified by QMPCR. Specifically, two tumours with a balanced allele ratio 
of the ANGPTL1–SNP had allelic imbalances at the SNPs located on 1q21 and 1q32. 
However, as the same SNP showed allelic imbalance in 5 tumours with allelic imbalances 
of the telomeric and centromeric SNPs, this discontinuity is not likely to be a simple 
systematic error. 
In principle, Real Time PCR permits detection of gain or loss of a single copy of a gene. 
Results from QMPCR and Real Time PCR were clearly correlated but the correlation 
coefficient was rather low. Goff et al. [56] suggested that the detection level of CGH was 
presumably below the one of Real Time PCR. However, with the same thresholds we 
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used for QMPCR (samples were considered to have gains if more than one marker 
showed a value equal or higher than 1.5), 76% of the tumours showed concordant results 
in the TaqMan and CGH assays.  
With array-CGH we identified gains of material on 1q in a higher proportion of tumours 
(12/17, 70%). In view of the low number of tumours investigated by array-CGH this 
might be due to random variation. In addition, it has to be noted that these tumours had 
been deliberately selected because they had given enough high quality RNA suited for 
expression analysis. It is possible that this bias contributes to the observed higher 
proportion of tumours with 1q gains. The results obtained by array-CGH were concordant 
with those of conventional CGH and QMPCR and, therefore, we have no reason to 
suspect that array-CGH will identify gains that are not detected by the other techniques. 
With QMPCR we detected gains in 13 of 50 tumours that had no 1q gains in CGH. This 
suggests that CGH fails to identify some tumours that in fact have 1q gains. Admittedly, 
we cannot exclude that some tumours identified as having gains by QMPCR have in fact 
no 1q gains. However we have controlled for stochastic and systematic errors, which both 
are potential sources of false positive results, by redundant measurements of some loci 
and by analysis of samples with known copy number of chromosome 1q, respectively.  
Moreover, our results confirm previous reports [31, 52] have also found that QMPCR has 
a higher sensitivity (i.e. lower proportion of false negatives) compared to that of CGH.  
The patterns of copy number changes do not converge on a single small interval on 1q 
that might be regarded as a minimal region of gains. Rather, two minimally regions of 
gains were identified: 1q21 and 1q32.1q32.2. It is to be noted that the centromeric region, 
1q21, was only identified after joint analysis of DNA copy number and expression data 
with the SAM method that had prompted us to perform QMPCR of loci in this region. 
Also with CGH we found that some cell lines showed a gain pattern with two peaks. In 
QMPCR, most of the 76 retinoblastomas showed increased copy numbers for loci from 
1q21 and 1q32. In most tumours with gains, the level of gains corresponds to a 
triplication. This is in accord with previous reports of trisomy of 1q [57]. 
All retinoblastoma cell lines that we analyzed had gains in both regions. However, most 
cell lines showed higher levels of gains compared to primary tumours. The high 
conservation of the pattern of gains in a retinoblastoma (G319) and a cell line (RBL 30) 
derived from this primary tumour suggests that the quantitative differences must not 
reflect alterations that occurred during cell culture. It is conceivable that only those 
primary tumours with relatively high levels of gains in these regions on 1q can be 
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established as cell lines. In other words, high level gains may be a prerequisite for 
successful permanent growth in cell culture. 
The two regions identified with QMPCR and CGH were not exactly the same as those 
identified with array-CGH. In array-CGH the centromeric border of gains was localized to 
1q22. However, the BACs with hybridization signals indicating gains are mapped to the 
boundary of 1q21 and 1q22. Therefore, the genes that are represented in these clones are 
either located on 1q21.3 or 1q22. This does not change the essence of our finding, namely 
that the patterns of gains in primary retinoblastoma and in cell lines that suggest two 
distinct regions on 1q are the targets of genomic gains in retinoblastoma.  
The mechanism underlying amplification on 1q is unknown. However, the formation of 
double minute chromosomes or episomes is very improbable for two reasons: i) in most 
of the tumours with gains, the whole long arm of chromosome 1 is triplicated, and ii) the 
level of gain is not high enough to be due to extra-chromosomal structures which usually 
induce amplifications of genes. The most probable mechanism involved in gains on 1q in 
retinoblastoma is duplication of one chromosome arm.  
Genomic gains on chromosome 1q are observed in many tumour entities including 
lipomas, leiomyosarcomas and osteosarcomas [58-60]. Interestingly, these are tumours 
that occur with increased frequency in patients with hereditary retinoblastoma (second 
extraocular tumours) [61, 62]. This suggests that retinoblastoma and second extraocular 
tumours may have in common some of the genetic alterations that are needed for 
initiation and progression. Lipomas and leiomyosarcomas frequently have amplifications 
on 1q21-q23 [63], which overlaps with one of the regions of gains identified here. Gains 
of material on 1q21 are also present in osteosarcomas, although at relatively low 
frequency [64, 65]. The second region with gains in retinoblastoma, 1q32, has been found 
to be involved in gene amplifications that were detected in other tumours. Specifically, a 
subset of glioma has high level amplifications on 1q32 that target the MDM4 gene [38, 
39]. We analyzed the pattern of 1q gains from two glioma samples with 1q amplification 
by QMPCR. Our data confirmed high level gains of MDM4 and GAC1 and moderate 
gains of PIK3C2B and PEPP3, which are also located in 1q32. This shows that the pattern 
of gains in the two glioma samples is unlike that of retinoblastoma and indicates that 
distinct sets of genes are targeted by gains in these two tumour entities. 
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4.1.2 Candidate genes on 1q 
 
As DNA gains in retinoblastoma do not focus on a small interval on 1q, additional data is 
required to narrow down the list of genes that might contribute to progression in this 
tumour. By joint analysis of data on DNA gains and on RNA expression, which we 
obtained from a subset of our samples, we could exclude a possible contribution of 
several genes located in regions with gains. For example, we found that MDM4, 
PIK3C2B, GAC1, and PEPP3, which are located in 1q32 and show gains in glioma with 
1q32 amplification, were absent or not differentially expressed between retinoblastomas 
with or without gains in this region. This confirms that these genes are not the target of 1q 
gains in retinoblastoma. Gains on 1q21-q23 in liposarcomas and leiomyosarcomas have 
been found to consistently include the COAS cluster of genes [63].  We found that one of 
these genes, COAS2, is not expressed at all in retinoblastomas. The two other genes of the 
COAS cluster (COAS1 and COAS3) are not represented on the Affymetrix chip we used. 
However, no data on expression of the COAS genes has been reported in liposarcomas or 
leiomyosarcomas and, therefore, their possible role in these tumours is also not resolved. 
The oligonucleotide array that we used for RNA analysis interrogated the expression of 
more than 22,000 probe sets. This represents a considerable proportion of human genes 
known so far. When analyzing the expression data by SAM, several genes located in 1q21 
and 1q32 were identified as differentially expressed between tumours with and without 
gains. Among them are CENPF, located on 1q41, and MCL1 and JTB, located on 1q21 
that have been associated with cancer previously.  
• CENPF (mitosin) encodes a protein of the nuclear matrix that associates with the 
centromere-kinetochore complex during mitosis. Higher expression of this gene 
has been associated with oesophageal squamous cell carcinoma [66], progression 
of astrocytoma [67] and of head and neck squamous cell carcinoma [68]. Among 
the genes with differential expression between retinoblastoma with and without 1q 
gains, CENPF has the highest fold change (2.14, q-value: 8.3%). In normal adult 
retina this gene is not expressed but this might simply reflect the low mitotic 
activity of this terminally differentiated tissue. The “electronic northern” of this 
gene ( http://expression.gnf.org and http://symatlas.gnf.org/SymAtlas/, Affymetrix 
accession # 207828_s_at) shows a median value of expression of 250 with a peak 
value of 5000 in bone marrow early erythroid cells. In comparison, the median 
obtained in retinoblastoma primary tumours is 4800, with highest values of 14600. 
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Such a high level of expression suggests that this gene is important for the biology 
of retinoblastoma. 
• MCL1 is another differentially expressed gene, which belongs to the Bcl-2 family 
and has been found to be overexpressed in anaplastic cell lymphoma cell lines and 
tumours [69, 70]. Transcripts of this gene show alternative splicing and two 
variants encoding distinct isoforms have been identified [71]. The product of the 
longer transcript enhances cell survival by inhibiting apoptosis while the 
alternatively spliced shorter gene product promotes apoptosis. We cannot 
distinguish these transcripts because the 3 different probe sets contained on the 
Affymetrix chip all detect both transcript variants. The electronic northern of 
MCL1 (Affymetrix accession # 200797_s_at) shows a median value of expression 
of 100 with a peak value of 12000 in myeloid cells. In retinoblastoma primary 
tumours the median obtained is 7000, and the highest value 9900. These 
expression levels show that MCL1 may play a role in the development of 
retinoblastoma. 
• A third gene higher expressed in tumours with gains on 1q, JTB (jumping 
translocation breakpoint), was found to be a part of an amplicon located on 1q21 
and overexpressed in hepatocellular carcinoma [72]. The function of JTB is not yet 
well characterised. 
Finally, differential expression was also identified for ZNF281, SYT11, ENSA, ADAR, 
LASS2, SNX27, SMYD3 and HTCD37. Two of these genes, ADAR and HTCD37, were not 
differentially expressed between normal retina and tumours with gains. SYT11, ZNF281, 
SNX27, SMYD3 and ENSA have a 2 fold lower expression in normal adult retina 
compared to the median in retinoblastomas with gains on 1q. Increased expression of 
these genes in tumours has not been reported and what is known about their function, if 
characterized at all, yields no specific clues to a possible role in tumour progression. 
Nevertheless, these genes should not be disregarded as potential functional targets of 1q 
gains in retinoblastoma.  
 
4.1.3 Clinical aspects 
 
In a previous CGH based study on tumours of patients selected for early and late age at 
diagnosis it was observed that patients with tumours with no detectable alteration on 1q 
were diagnosed earlier compared to patients with tumours with gains [28]. With the copy 
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numbers determined by QMPCR in this study we could use clustering algorithms to 
classify tumours according to the pattern of 1q gains. When stratifying according to the 
classes obtained by this analysis, earlier diagnosis of tumours without 1q gains is evident. 
Interestingly, tumours with 1q intermediate gains show a significant lateral shift of the 
distribution towards older age at diagnosis compared to tumours without gains. Tumours 
with high gains and very high gains were diagnosed even later. They show almost the 
same distribution of age at diagnosis thus indicating that these two classes of tumours are 
not distinct with regard to their biologic behaviour. Different hypotheses can be put 
forward to explain the observed relation between 1q gains and age at diagnosis. Assuming 
that retinoblastoma development is initiated by mutations in both alleles of the RB1 gene, 
the time course of tumour initiation should not be dependent on the presence of 1q gains. 
Also, tumour size at the time of diagnosis tends not to be larger in tumours with 1q gains 
(P=0.0640, Chi-Squared Test for trend, classes chg and hg combined) and, therefore, it is 
unlikely that tumours with and without 1q gains represent consecutive stages in the 
development of retinoblastoma. One hypothesis that may be derived from our 
observations is that tumours without 1q gains grow faster and thus reach the size required 
to be detected earlier than tumours with 1q gains. This might also account for our 
observation that vitreous seeding is more frequent in tumours with gains on 1q (P=0.0397 
Chi-Squared Test for independence, classes chg and hg combined) because if tumours 
with 1q gains develop with a slow kinetic this would provide more time for seeding into 
the vitreous. It has been proposed by Gallie et al. (1999) that, in addition to mutational 
inactivation of both RB1 alleles, third mutations (M3) are required for retinoblastoma 
development. Assuming this model, tumours without 1q gains may have other M3 
mutations in their genome that result in faster progression compared to tumours with 1q 
gains.  
In conclusion, we identified a significant correlation between the time of clinical 
manifestation and the presence of 1q gains, which is evident even in retinoblastomas with 
low-level copy number changes. 
 
4.2 Gains on the short arm of chromosome 1  
 
In one of 17 retinoblastomas examined by whole genome matrix-CGH a genomic region 
on the short arm of chromosome 1 (1p34.2) was found to be amplified. This novel finding 
pointed our attention to the genes contained in the four BACs that represent this region. 
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Of the 9 different genes known to be located on these clones, 8 were also overexpressed 
in RNA from this single tumour. When combining data from the whole genome matrix-
CGH and from expression analysis it is possible to delimit the size of the amplicon to an 
850 kb region that is framed by the PPIE gene on the telomeric side and the NFYC on the 
centromeric side. The size of the amplicon suggests that it may have its origin in an extra-
chromosomal structure, possibly a double minute chromosome. Such structures have been 
described [57] in retinoblastoma cell lines.  
The amplicon contains 8 known genes (TRIT1, MYCL1, CAP1, PPT1, RLF, ZMPSTE24, 
COL9A2 and RIMS3): 
• PPT1, palmitoyl-protein thioesterase 1, is a small glycoprotein that removes palmitate 
groups from cysteine residues in lipid-modified proteins and is thought to be involved 
in the catabolism of lipid-modified proteins. 
• CAP1, adenylate cyclase-associated protein 1, encodes a protein involved in the cyclic 
AMP pathway. 
• ZMPSTE24 encodes a zinc metalloprotease found in the endoplasmic reticulum and 
possibly in the Golgi compartment. It is thought to be involved in the proteolytic 
processing of farnesylated proteins. 
• COL9A2 encodes one of the three alpha chains of type IX collagen, a component of 
hyaline cartilage.  
The functions of the remaining three genes, TRIT1 (tRNA isopentenyltransferase 1), 
RIMS3 (regulating synaptic membrane exocytosis 3), and RLF   (rearranged L-myc fusion 
sequence), are not a well characterised. 
MYCL1, an acronym which stands for v-myc myelocytomatosis viral oncogene homolog 
1, has been found to be activated in different types of cancer [53-55]. MYCL1, is a 
member of the myc family of transcription factors. Members of this gene family are 
known to play important roles in the progression of cancers. Therefore, the MYCL1 is a 
prime candidate for the functional target of this gene amplification. The myc family genes 
are all composed of 3 exons and 2 introns. MYCL1, which is less well characterised than 
c-MYC, is the third member of this family. c-MYC is thought to be involved in the 
progression of osteosarcomas, glioblastomas, melanomas [73-75] when its expression is 
elevated or deregulated. The MYCL1 gene is processed into two mRNA that code for two 
related proteins (short and long form). The only probe set specific to MYCL1 on the 
Affymetrix chip does not allow to distinguish between the two mRNAs. The long form of 
MYCL1 is associated with the nucleus of the cells, whereas the short form seems to be 
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expressed also in the cytoplasm [76]. The half lives of both long and short peptides are 
relatively short. De Greve et al., Kaye et al. and Ikegaki et al. [53, 76, 77] found that 
MYCL1 is amplified and overexpressed in small cell lung carcinoma cell lines. This gene 
was also amplified and overexpressed in other tumour types including ovarian carcinoma 
[55] and hormone resistant prostate cancer [54]. Another member of the myc family, 
MYCN, has been found to be amplified in retinoblastoma cell lines and, infrequently, in 
primary tumours. Doz et al. [78] identified gains in only 1 of 45 primary retinoblastomas 
while in a report by Kim et al. [79] 6 of 33 primary tumours were amplified. In the latter 
study, tumours with MYCN gains had higher proliferation levels compared to tumours 
without amplification. Gains and overexpression of MYCL1 in retinoblastoma has not 
been reported before. The patient who carried this tumour had unilateral isolated 
retinoblastoma, and showed a mutation in blood DNA (inherited from the mother). In 
addition to MYCL1 amplification this tumour showed gains on 6p and 19q and losses on 
13q. 
 
4.3 Candidate tumour suppressor genes on the long arm of chromosome 16 
 
We identified allele loss of at least one informative polymorphic marker on 16q in 4 of 21 
(19%) retinoblastomas. This compares well with the frequency of reported chromosome 
16 alterations in CGH analyses which ranges from 14 to 34% of tumours. The minimal 
region lost on 16q, which was delimited to 16q22 in several CGH based studies [25-28], 
contains a cluster of cadherin genes. Cadherins are Ca2+-dependant cell-cell adhesion 
molecules which interact with intracellular proteins (catenins, plakoglobins, desmoplakin 
[80]). The proteins from the cadherin superfamily have functions in cell adhesion, 
cytoskeletal organisation, signal transduction, and growth control. CDH1 (or E-cadherin) 
is the most studied and best characterised member of this family. Loss of function of 
CDH1 contributes to progression in cancer by increasing proliferation and invasion. It is 
involved in many different type of tumours including brain tumour [81] and breast 
carcinomas [82]. In some colon and rectal cancers silencing of the CDH1 gene by 
hypermethylation of its promoter has been found [83]. In a recent study, Marchong et al. 
pointed to CDH11 as target of loss on chromosome 16. CDH11 (OB-cadherin) is 
expressed in osteoblastic cell lines and its up-regulation during differentiation suggests a 
specific function in bone development and maintenance. Kawaguchi et al. [84]  suggested 
that reduced expression of CDH11 in osteoblasts is associated with local invasion of 
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osteosarcoma. Because of the association between osteosarcoma and hereditary 
retinoblastoma we investigated the methylation status of the CpG islands in the promoter 
of CDH11 gene but identified no abnormality in any of 58 tumours. Thus our data do not 
support the hypothesis that CDH11 is inactivated in retinoblastoma. 
In three of the four retinoblastomas with allele loss, all informative markers on 16q 
showed LOH. This is compatible with loss of one whole of long arm of this chromosome 
(deletion) or mitotic recombination, which results in isodisomy of 16q. In one 
retinoblastoma (M24794), only the STR-marker D16S3085, which is located between two 
markers in the CDH3 and CDH5 genes, showed LOH. We used pyrosequencing of SNPs 
to delimitate more precisely the region lost in this tumour. Unfortunately, SNP 
genotyping in this tumour was hampered by constitutional homozygosity of SNPs next to 
the STR-marker D16S3085 with LOH. Therefore, we could not further narrow down the 
minimum region of loss in tumour M24794. Based on available data, the minimum region 
of LOH has 1,270 kb (NCBI database) and contains 75 genes. Specifically, this region 
does not include the gene CDH11 (1.5 Mb away, NCBI database) and this in line with the 
negative results that we obtained by promoter methylation analysis of this gene. Among 
the 75 genes in this region, 28 are well characterised and some of them have been shown 
to have a role in tumorigenesis:  
• The gene E2F4 is a transcription factor playing a role in the control of cell cycle 
and binding to different tumour suppressor proteins such as pRB. The protein of 
this gene can induce both proliferation and apoptosis, the function is tissue 
specific. Its reduced expression is thought to play a role in breast carcinoma [85].  
• CTCF (CCCTC-binding factor) is a transcription factor whose targets are, as 
E2F4, either oncogenes or tumour suppressor genes, and it has been proposed that 
it has a tumour suppressor role in breast, prostate, and Wilms' tumours [86].  
• The CBFB gene (core-binding factor, beta subunit) is a transcription factor whose 
down-regulation has been observed in gastric cancers [87].  
• Hsu et al. [88] found that overexpression of TRADD (tumour necrosis factor 
receptor 1 associated via death domain) led to 2 major TNF-induced responses, 
apoptosis and activation of NF-kappa-B.  
• HSD11B2 (hydroxysteroid (11-beta) dehydrogenase 2) is underexpressed in 
colorectal cancer [89], in pituitary adenomas [90] and in cortisol-secreting 
adenomas [91]. 
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Including the data of expression analysis of the genes in the minimal LOH region defined 
by D16S3085 was of no help to identify potential candidate genes. For example, the 
tumours with LOH did not show a reduced expression of the CDH genes compared to 
tumours without loss. Among the genes located in the minimal region of loss and 
involved in tumour progression (described above), only CBFB showed differential 
expression between tumour with and without allele loss. The difference of the median 
expression in tumours with LOH was 3,200 whereas the median expression in tumours 
without LOH was 5,300. As is to be expected from the small sample and effect size, this 
difference is not statistically significant (Wilcoxon test normal approximation P>0.5). 
This is also true for another gene, APPBP1 (amyloid beta precursor protein binding 
protein 1), which showed a two fold lower expression in tumours with LOH compared to 
tumours with both alleles. 
In summary, based on the spatial pattern of allele loss and the results of methylation 
analysis it is unlikely that CDH11 is the target of loss on 16q. In view of the relatively 
low frequency of retinoblastomas with LOH of only parts of 16q, it is likely that a larger 
panel of tumours must be analyzed in order to map the boundaries of the minimum region 
of deletion.  
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5 CONCLUSION 
 
We have identified genetic alterations that occur during the development of 
retinoblastoma. Specifically, we have found that, in addition to gains on 1q32, gains are 
also frequent in 1q21. The pattern of DNA gains and the results of our expression analysis 
did not point to specific genes as the major targets of these alterations. However, age at 
clinical manifestation is correlated with the presence of 1q gains and this suggests that the 
deregulation of gene expression patterns caused by 1q gains is important for the clinical 
behaviour of this tumour, and like in other tumour entities [92] genomic gains that result 
in altered expression of several genes can have a tumour promoting effect. It will be 
difficult to identify the individual contribution of these genes to progression compared to 
the situation in tumours with high-level amplification of a small genomic region and, as a 
result of this, overexpression of a single gene [93]. However, the strong association with 
clinical manifestation suggests that identification of the functional targets of these 
changes will improve our understanding of the biology of this tumour. 
 
Our data confirm that the minimum region of allele loss on chromosome 16 is located on 
16q22. Our results also suggest that CDH11 is not the target of loss of function mutations. 
Therefore, further analysis will be necessary to define precisely which gene or genes are 
involved in retinoblastoma progression.  
 
We have identified a novel target of DNA gains in retinoblastoma that is located on the 
long arm of chromosome 1. This region contains several genes including the MYCL1 
gene, which is a potential oncogene. These genes are overexpressed when compared to 
tumours without amplification. Further analyses are required to determine which of these 
genes contribute to the progression of retinoblastoma. 
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6 ABSTRACT 
 
Many retinoblastomas (RBs) show genomic alterations in addition to mutational loss of 
both normal RB1 alleles. The most frequent of these changes are gains on chromosomes 
1q and 6p and losses on 16q. To identify the genes targeted by gains on chromosome 1q 
we used quantitative-multiplex PCR and array-CGH to determine DNA copy number 
changes in 76 primary tumours and 6 RB cell lines. In addition, in 21 of these tumours 
gene expression was analyzed by cDNA microarray hybridization. We have used 
microsatellite analysis and pyrosequencing to further localise the region of allele loss of 
heterozygosity on chromosome 16. We have also set up a specific methylation assay for 
the CDH11 gene located on 16p22 that was previously considered to be the target of loss 
on 16. The results we obtained were compared with expression of the corresponding 
genes. A novel region of amplification on the short arm of chromosome 1 was determined 
with array-CGH, and with a combination of genomic results and expression data allowed 
us to analyse the possibility of a novel oncogene involved in progression of 
retinoblastoma. 
Increased copy numbers of loci on chromosome 1q were present in 34 (45%) primary 
tumours and in all 6 cell lines. Two regions of gain emerged, one in 1q32 and another in 
1q21. Tumours with 1q gains showed higher RNA expression of several genes in these 
two regions. The clinical manifestation of tumours with and without gains was similar 
with regard to many aspects including size, necrosis and calcification. However, the 
distribution of age at diagnosis was remarkably distinct with earlier diagnosis in tumours 
without gains. This suggests that these tumours are either initiated earlier or grow faster 
than tumours with gains. This association with clinical manifestation indicates that gains 
on 1q are significant for the biology of retinoblastoma. The genes on 1q with copy 
number gains and overexpression here are candidates that need to be tested for their 
individual contribution to the progression of retinoblastoma. The targets of loss on 
chromosome 16 are not clearly identified, but our results suggest that the CDH11 gene is 
probably not the tumour suppressor gene involved in progression of retinoblastoma that 
was proposed before. The results we obtained with our analyses on chromosome 1p 
suggest a role for MYCL1 in retinoblastoma. 
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7 ANNEXES 
 
Table A. 150 first genes overexpressed in tumours with gains on 
1q (from SAM) 
 
Affy. # Location Fold 
Change 
q-value 
(%) 
218401_s_at Chr:1q32.1 1.51 4.90 
209197_at Chr:1q21.2 1.43 4.90 
221486_at Chr:1q21.2 1.62 4.90 
209198_s_at Chr:1q21.2 1.69 4.90 
201786_s_at Chr:1q21.1-q21.2 1.33 4.90 
210101_x_at Chr:1p22 1.41 4.90 
200797_s_at Chr:1q21 1.38 4.90 
209091_s_at Chr:1p22 1.48 4.90 
220483_s_at Chr:8q22 1.38 4.90 
209586_s_at Chr:1q21 1.70 4.90 
200897_s_at Chr:4q32.3 1.66 4.90 
221498_at Chr:1q21.2 1.48 5.52 
222212_s_at Chr:1q21.2 1.63 5.52 
220199_s_at Chr:1q42.12 2.44 5.52 
200723_s_at Chr:11p13 1.38 5.52 
218576_s_at Chr:1q21-q22 1.42 5.52 
218229_s_at Chr:1q23.2 1.46 5.52 
204508_s_at Chr:15q21.3 3.99 5.52 
214464_at Chr:1q42.11 1.55 5.52 
218928_s_at Chr:21q22.3 2.63 5.52 
218107_at Chr:1q42.12 1.40 5.52 
210927_x_at Chr:1q21 1.48 6.38 
210438_x_at Chr:1q31 1.48 6.59 
211963_s_at Chr:1q25.1 1.53 6.59 
211578_s_at Chr:17q23.2 1.54 8.30 
210434_x_at Chr:1q21 1.55 8.30 
212165_at Chr:1q31.3 1.63 8.30 
212871_at Chr:12q24.13 1.36 8.30 
215720_s_at Chr:6p21.3 4.11 8.30 
203748_x_at Chr:2q24.2 2.74 8.30 
222250_s_at Chr:1p36.13-q42.3 1.45 8.30 
217797_at Chr:1q23.1 1.50 8.30 
207828_s_at Chr:1q32-q41 2.14 8.30 
212219_at Chr:2p16.1 1.78 8.30 
202313_at Chr:8p21.1 1.60 8.30 
200030_s_at Chr:12q23 1.27 8.30 
207266_x_at Chr:2q24.2 3.19 8.48 
212405_s_at Chr:1q24-q25.3 1.54 9.94 
212746_s_at Chr:1q44 1.72 10.17 
205240_at Chr:1p13.2 1.76 10.17 
46665_at Chr:2q11.1 1.63 10.17 
201027_s_at Chr:2p11.1-q11.1 1.54 10.17 
221230_s_at Chr:1q42.1-q43 1.47 10.17 
214104_at --- 2.98 10.17 
201796_s_at Chr:6p21.3 2.33 10.17 
213997_at Chr:15q12 2.63 10.17 
212429_s_at Chr:2p23.3 1.45 10.17 
209647_s_at Chr:2p21 1.40 11.44 
 78
Annexes   
201514_s_at Chr:5q33.1 1.53 12.08 
208490_x_at Chr:6p21.3 1.80 12.08 
201771_at Chr:1q21 1.50 12.08 
212773_s_at Chr:1q42 1.55 12.08 
218293_x_at Chr:22q13.31 2.48 12.08 
201841_s_at Chr:7q11.23 2.02 12.08 
210052_s_at Chr:20q11.2 1.66 12.08 
220042_x_at Chr:1p34 1.88 12.08 
221772_s_at Chr:10q26.3 4.87 12.08 
217864_s_at Chr:15q 1.36 12.08 
202251_at Chr:1q21.1 1.41 12.08 
214943_s_at Chr:1q42.3 1.69 12.08 
217885_at Chr:1q31.3 1.36 12.08 
215157_x_at Chr:8q22.2-q23 1.33 12.08 
218865_at Chr:1q42.11 2.29 12.08 
201112_s_at Chr:20q13 1.38 12.08 
221258_s_at Chr:11p14.1 1.58 12.08 
212591_at Chr:1q42.3 1.58 12.08 
212072_s_at --- 1.32 12.08 
203155_at Chr:1q21 1.52 12.08 
202615_at --- 1.30 12.08 
201387_s_at Chr:4p14 1.60 12.08 
210697_at Chr:19q13 2.55 12.08 
219536_s_at Chr:20q13.13 2.60 12.08 
212498_at --- 1.30 12.08 
221487_s_at Chr:1q21.2 1.60 12.08 
220768_s_at Chr:5q23 1.77 12.08 
208778_s_at Chr:6q25-q27 1.28 12.08 
218336_at Chr:1q23.1 1.72 12.08 
204914_s_at --- 3.21 12.08 
201897_s_at Chr:1q21.2 1.98 12.08 
209771_x_at Chr:6q21 8.04 12.08 
205046_at Chr:4q24-q25 1.63 12.08 
204477_at Chr:1q32-q41 1.45 12.08 
206571_s_at Chr:2q11.2-q12 1.41 12.08 
201150_s_at Chr:22q12.3 1.99 12.08 
219918_s_at Chr:1q31 1.98 12.94 
207108_s_at Chr:5p13.2 1.42 12.94 
203550_s_at Chr:1q21 1.73 12.94 
219120_at Chr:2p24.1 1.60 12.94 
203853_s_at Chr:11q13.3 1.93 13.85 
201148_s_at Chr:22q12.3 1.51 13.85 
212402_at Chr:13q14.11 1.37 13.85 
204366_s_at Chr:2p23.3 1.62 13.85 
200065_s_at Chr:1q42 1.40 13.85 
218728_s_at Chr:1q42.12 1.63 13.85 
203313_s_at Chr:18p11.3 1.77 13.85 
208796_s_at Chr:5q32-q34 1.55 13.85 
215158_s_at Chr:1q23.1 1.30 13.85 
205661_s_at Chr:1q21.3 1.35 13.85 
206928_at Chr:1q44 1.68 14.83 
201241_at Chr:2p24 1.45 14.83 
214548_x_at Chr:20q13.2-q13.3 1.44 14.83 
208744_x_at Chr:13q12.2 1.75 15.79 
204108_at Chr:6p21.3 1.99 15.79 
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205070_at Chr:7q31 1.34 15.79 
203099_s_at Chr:6p25.1 5.61 15.79 
218223_s_at Chr:1q21.2 2.97 15.79 
218784_s_at Chr:6p21.1 1.59 15.79 
215509_s_at --- 1.93 15.79 
202559_x_at Chr:1q21.3 1.33 15.79 
212599_at Chr:7q11.21 1.66 15.79 
200652_at Chr:1q21-q23 1.81 15.79 
201289_at Chr:1p31-p22 2.65 15.79 
204195_s_at Chr:21q22.3 2.13 15.79 
201966_at Chr:1q23 1.30 15.79 
210243_s_at Chr:1q21-q23 1.75 15.79 
215227_x_at Chr:2p25 1.53 15.79 
201938_at Chr:12q24.31 1.27 15.79 
209825_s_at Chr:1q23 1.67 15.79 
221741_s_at Chr:20q13.33 1.32 15.79 
202786_at Chr:2q31.1 1.68 15.79 
212153_at Chr:1q21.2 1.37 15.79 
218856_at Chr:6p21.1-12.2 2.64 15.79 
203755_at Chr:15q15 1.52 15.79 
208720_s_at Chr:20q11.21 1.23 15.79 
200666_s_at Chr:19p13.2 1.47 15.79 
202388_at Chr:1q31 1.69 15.79 
211609_x_at Chr:1q21.2 1.64 16.77 
207164_s_at Chr:1q44-qter 1.48 16.77 
204915_s_at Chr:2p25 3.32 16.77 
208854_s_at Chr:13q31.2-q32.3 1.38 16.77 
217919_s_at Chr:12q22 1.57 16.77 
216379_x_at Chr:6q22 7.69 16.77 
202743_at Chr:1p33 1.57 17.57 
216048_s_at Chr:5q14.3 1.39 17.57 
201023_at Chr:5q31 1.22 17.57 
218507_at Chr:7q32.2 1.32 17.57 
208655_at Chr:4q21.21 1.50 17.57 
204031_s_at Chr:12q13.12 1.35 17.57 
210387_at Chr:6p21.3 2.52 17.57 
212650_at Chr:2p14 1.47 17.57 
204373_s_at Chr:1p36.13-q41 1.33 17.57 
204471_at Chr:3q13.1-q13.2 5.07 18.55 
218177_at Chr:18p11.21 1.38 18.55 
210053_at --- 1.44 18.55 
218755_at Chr:5q31 1.56 18.55 
219867_at Chr:21q11.2 5.14 18.55 
212442_s_at Chr:2q31.1 1.75 18.55 
221959_at Chr:8q11.23 2.81 18.55 
212902_at Chr:5q31.1 1.22 19.01 
203098_at Chr:6p25.1 2.11 19.01 
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